Methods and agents for treating acute neuroinflammatory injuries
Treating acute neuroinflammatory injuries, especially stroke, with CD14-targeting antibody therapy addresses the shortcomings of existing treatments, achieving effective reduction of neuroinflammatory response and improvement of neurological function within 6 hours after stroke.
Patent Information
- Application Number
- CN202080067788.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-07-25
- Filing Date
- 2020-07-24
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2040-07-24
AI Technical Summary
Current technologies lack effective treatments for acute neuroinflammatory injuries, such as stroke and hypoxic-ischemic brain injury. In particular, traditional thrombolytic therapy has limited effectiveness and carries the risk of bleeding during the 3 to 4.5 hour window after a stroke, resulting in most patients not receiving timely and effective treatment.
By using CD14 antagonist antibodies, single or multiple doses of CD14 antagonist antibodies can be administered systemically to target the CD14 receptor, inhibit the DAMP/CD14/TLR axis, reduce the release of pro-inflammatory cytokines, and alleviate neuroinflammatory responses.
Administering CD14 antagonist antibodies within 6 hours of stroke significantly reduces neurological deficits and infarct size, providing an effective treatment option outside the traditional treatment window and improving patients' chances of recovery.
Smart Images

Figure CN114450068B_ABST
Abstract
Description
[0001] Cross-references to related applications
[0002] This application claims priority to Australian Provisional Application No. 2019902642, filed on 25 July 2019, entitled “Methods and agents for treating acute neuroinflammatory injury,” the contents of which are incorporated herein by reference in their entirety.
[0003] By referencing and incorporating into the sequence list
[0004] This application is submitted together with an electronic sequence list. The sequence list is provided as a file titled 229752008140SeqList.TXT, created on July 24, 2020, and is 15,258 bytes in size. Information from the electronic sequence list is incorporated in its entirety by reference. Invention Field
[0005] This disclosure generally relates to methods and agents for treating acute neuroinflammatory injuries such as stroke (e.g., ischemic or hemorrhagic stroke), hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage, and cerebral hemorrhage. Specifically, this disclosure relates to the use of CD14 antagonist antibodies for treating acute neuroinflammatory injuries. Background of the Invention
[0007] Stroke is a leading cause of death and disability worldwide and is listed as the leading neurological burden in developed countries. Stroke is caused by the blockage or rupture of a blood vessel in the brain. The interruption of blood flow to the brain leads to nerve damage and irreversible, long-term sensorimotor deficits. This damage is caused by energy depletion, excitotoxicity, peri-infarct depolarization, inflammation, and programmed cell death. There are two common types of stroke: (i) ischemic stroke, which is caused by a temporary or permanent blockage of blood flow to the brain and accounts for 85% of stroke cases; and (ii) hemorrhagic stroke, which is caused by a ruptured blood vessel and accounts for the majority of the remaining cases. The most common cause of ischemic stroke is occlusion of the middle cerebral artery (an intracranial artery downstream of the internal carotid artery), which damages the brain. Such damage results in hemiplegia, partial paralysis, and, depending on the affected hemisphere, language or visuospatial deficits. Only about 50% of patients with hemorrhagic stroke survive, compared to 85% of patients with ischemic stroke. However, with only about 10% achieving full recovery, most stroke patients suffer long-term, debilitating damage to their physical, mental, and social well-being.
[0008] One of the leading causes of death and disability from stroke is the lack of appropriate and effective treatment. There are no other treatments available for acute stroke except recanalization. For patients with ischemic stroke, early intervention to restore blood flow to the affected area of the brain can limit the extent of damage and increase the patient's chances of recovery. This treatment can include thrombolysis (e.g., via intravenous administration of tissue plasminogen activator) or thrombectomy (which involves the physical removal of the clot from the brain). While thrombolysis administered up to 4.5 hours after symptom onset has been shown to improve recovery, very few stroke patients benefit from this treatment, primarily due to delayed hospital admission or unknown onset time. It is also noteworthy that thrombolysis administered more than 3 hours after stroke carries a significantly associated risk of bleeding. Therefore, there is a short window of opportunity for thrombolysis, typically 3 to 4.5 hours after stroke. It is estimated that less than 15% of stroke patients admitted to the hospital are therefore eligible for thrombolysis. The percentage of stroke patients eligible for thrombectomy is even lower, approximately 10%.
[0009] Therefore, there remains a need for additional agents and methods for treating stroke and other acute neuroinflammatory injuries. Invention Overview
[0011] This invention stems in part from the surprising finding that targeting differentiation cluster 14 (CD14) (such as by administration of an anti-CD14 antagonist antibody, e.g., systemic administration) can treat stroke and prevent, reduce, or improve stroke-related symptoms such as infarct size, functional decline, neurological deficits, and edema. Surprisingly, as demonstrated herein, targeting CD14 with a single dose of the antagonist antibody (e.g., 6 hours after stroke) significantly reduces neurological deficits, functional decline, and infarct size. Conversely, prolonged dosing regimens (e.g., 7 days) are less effective.
[0012] Hypoxic neurons, such as those induced by stroke, generate multiple types of damage-associated molecular patterns (DAMPs). These DAMPs activate Toll-like receptors (TLRs) and their co-receptor CD14 located on microglia, monocytes, and peripheral macrophages (innate immune cells). The DAMP / CD14 / TLR axis connects to activate microglia / macrophages and promotes the release of pro-inflammatory cytokines mediating injury. Multiple TLRs are activated by multiple DAMPs in neuronal injury, each contributing to the stroke outcome. However, many of these DAMP / TLR interactions require co-activation with CD14 for effective signal transduction. Without being bound by theory, it is suggested that targeting CD14 modulates DAMP-driven neuroinflammation following stroke or other acute neuroinflammatory injuries in the acute phase (e.g., up to 48 hours post-injury) or the early subacute phase (e.g., up to 4 days post-injury), thereby alleviating symptoms of stroke or other acute neuroinflammatory injuries. Conversely, targeting CD14 in the late subacute or chronic phase (i.e., more than 4 days after injury) may be undesirable, as CD14+ immune cells may be important contributors to nerve repair and regeneration during this period.
[0013] However, as this article demonstrates, the results of weakening the DAMP / CD14 TLR axis with anti-CD14 antagonist antibodies in cases of stroke or other acute neuroinflammatory injuries appear to be fundamentally unpredictable in previously published studies. For example, it has been shown that modulation of CD14 by gene ablation leads to larger infarcts and worse outcomes in mouse models of stroke (Janova et al., Glia, 2016, 64, 635–649).
[0014] The effectiveness of a single dose of anti-CD14 antagonist antibody administered within 6 hours of stroke is not only surprising but also of significant clinical importance. Most stroke patients are not diagnosed until 6–12 hours after the stroke. Therefore, the earliest stroke intervention should be effective at least 6 hours after the stroke. Current thrombolytic therapy is only effective within 3 to 4.5 hours after stroke because bleeding may occur in the brain after this period. Therefore, the use of anti-CD14 antagonist antibodies effective 6 hours or more after stroke represents a significant clinical improvement over current stroke treatment and further represents a potential new treatment for other acute neuroinflammatory injuries, such as hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage, and intracerebral hemorrhage.
[0015] Therefore, in one aspect, this disclosure provides a method for treating acute neuroinflammatory injury in a human subject, the method comprising, consisting of, or substantially consisting of: administering an effective amount of a CD14 antagonist antibody to the subject, wherein the antibody is administered to the subject at most 48 hours after the injury.
[0016] In another aspect, this disclosure provides a method for treating acute neuroinflammatory injury in a human subject, the method comprising, consisting of, or substantially consisting of: systemic administration of an effective amount of a CD14 antagonist antibody to the subject, wherein the antibody is administered alone. In some embodiments, the antibody is administered to the subject at most 48 hours after the injury.
[0017] Another aspect of this disclosure provides a method for treating acute neuroinflammatory injury in a human subject, the method comprising, consisting of, or substantially consisting of: administering an effective amount of a CD14 antagonist antibody to the subject, wherein the antibody is administered as a single dose. In some embodiments, the antibody is administered to the subject at most 48 hours after the injury.
[0018] In another aspect, this disclosure provides a method for treating acute neuroinflammatory injury in a human subject, the method comprising, consisting of, or substantially consisting of: administering an effective amount of a CD14 antagonist antibody to the subject, wherein the CD14 antagonist antibody is selected from: (i) antibodies comprising: a) an antibody VL domain comprising L-CDR1, L-CDR2, and L-CDR3 or an antigen-binding fragment thereof, wherein: L-CDR1 comprises the sequence RASESVDSFGNSFMH [SEQ ID NO:7] (3C10 L-CDR1); L-CDR2 comprises the sequence RAANLES [SEQ ID NO:8] (3C10 L-CDR2); and L-CDR3 comprises the sequence QQSYEDPWT [SEQ ID NO:9] (3C10 L-CDR3); and b) an antibody VH domain comprising H-CDR1, H-CDR2, and H-CDR3 or an antigen-binding fragment thereof, wherein: H-CDR1 comprises the sequence SYAMS [SEQ ID NO:8] (3C10 L-CDR3); L-CDR1 contains the sequence SISSGGTTYYPDNVKG [SEQ ID NO:11] (3C10 H-CDR2); and L-CDR3 contains the sequence GYYDYHY [SEQ ID NO:12] (3C10 H-CDR3); (ii) an antibody containing: a) an antibody VL domain or an antigen-binding fragment thereof containing L-CDR1, L-CDR2 and L-CDR3, wherein: L-CDR1 contains the sequence RASESVDSYVNSFLH [SEQ ID NO:13] (28C5 L-CDR1); L-CDR2 contains the sequence RASNLQS [SEQ ID NO:14] (28C5 L-CDR2); and L-CDR3 contains the sequence QQSNEDPTT [SEQ ID NO:15] (28C5 L-CDR1). (i) L-CDR3); and (ii) antibody containing the VH domain of H-CDR1, H-CDR2 and H-CDR3 or an antigen-binding fragment thereof, wherein: H-CDR1 contains the sequence SDSAWN [SEQ ID NO:16] (28C5 H-CDR1); H-CDR2 contains the sequence YISYSGSTSYNPSLKS [SEQ ID NO:17] (28C5 H-CDR2); and H-CDR3 contains the sequence GLRFAY [SEQ ID NO:18] (28C5 H-CDR3); and (iii) antibody containing: a) antibody containing the VL domain of L-CDR1, L-CDR2 and L-CDR3 or an antigen-binding fragment thereof, wherein: L-CDR1 contains the sequence RASQDIKNYLN [SEQ ID NO:
[19] (18E12 L-CDR1);L-CDR2 comprises the sequence YTSRLHS [SEQ ID NO:20] (18E12 L-CDR2); and L-CDR3 comprises the sequence QRGDTLPWT [SEQ ID NO:21] (18E12 L-CDR3); and b) an antibody VH domain or antigen-binding fragment thereof comprising H-CDR1, H-CDR2, and H-CDR3, wherein: H-CDR1 comprises the sequence NYDIS [SEQ ID NO:22] (18E12 H-CDR1); H-CDR2 comprises the sequence VIWTSGGTNYNSAFMS [SEQ ID NO:23] (18E12 H-CDR2); and H-CDR3 comprises the sequence GDGNFYLYNFDY [SEQ ID NO:24] (18E12 H-CDR3). In some embodiments, the antibody is administered to the subject up to 48 hours after injury.
[0019] In specific embodiments of the above methods, the antibody is administered to the subject at most 12, 18, or 24 hours after injury. For example, the antibody may be administered to the subject between 2 and 48 hours, 4 and 48 hours, 6 and 48 hours, 2 and 24 hours, 4 and 24 hours, 6 and 24 hours, 2 and 18 hours, 4 and 18 hours, 6 and 18 hours, 2 and 12 hours, 4 and 12 hours, or 6 and 12 hours after injury. In another embodiment, the antibody is administered as a single dose.
[0020] In some embodiments, the antibody is selected from: (i) antibodies comprising: a) an antibody VL domain comprising L-CDR1, L-CDR2, and L-CDR3 or an antigen-binding fragment thereof, wherein: L-CDR1 comprises the sequence RASESVDSFGNSFMH [SEQ ID NO:7] (3C10 L-CDR1); L-CDR2 comprises the sequence RAANLES [SEQ ID NO:8] (3C10 L-CDR2); and L-CDR3 comprises the sequence QQSYEDPWT [SEQ ID NO:9] (3C10 L-CDR3); and b) an antibody VH domain comprising H-CDR1, H-CDR2, and H-CDR3 or an antigen-binding fragment thereof, wherein: H-CDR1 comprises the sequence SYAMS [SEQ ID NO:10] (3C10 H-CDR1); H-CDR2 comprises the sequence SISSGGTTYYPDNVKG [SEQ ID NO:11] (3C10 H-CDR1); (i) contains the sequence GYYDYHY[SEQ ID NO:12](3C10 H-CDR3); and (ii) contains the following antibodies: a) antibody VL domains or antigen-binding fragments thereof comprising L-CDR1, L-CDR2 and L-CDR3, wherein: L-CDR1 contains the sequence RASESVDSYVNSFLH[SEQ ID NO:13](28C5 L-CDR1); L-CDR2 contains the sequence RASNLQS[SEQ ID NO:14](28C5 L-CDR2); and L-CDR3 contains the sequence QQSNEDPTT[SEQ ID NO:15](28C5 L-CDR3); and b) antibody VH domains or antigen-binding fragments thereof comprising H-CDR1, H-CDR2 and H-CDR3, wherein: H-CDR1 contains the sequence SDSAWN[SEQ ID NO:16](28C5 H-CDR1); H-CDR2 contains the sequence YISYSGSTSYNPSLKS [SEQ ID NO:17] (28C5 H-CDR2); and H-CDR3 contains the sequence GLRFAY [SEQ ID NO:18] (28C5 H-CDR3); and (iii) antibodies containing: a) antibody VL domains or antigen-binding fragments thereof containing L-CDR1, L-CDR2 and L-CDR3, wherein: L-CDR1 contains the sequence RASQDIKNYLN [SEQ ID NO:19] (18E12 L-CDR1); L-CDR2 contains the sequence YTSRLHS [SEQ ID NO:20] (18E12 L-CDR2); and L-CDR3 contains the sequence QRGDTLPWT [SEQ ID NO:21] (18E12 L-CDR3);and b) an antibody VH domain or antigen-binding fragment thereof comprising H-CDR1, H-CDR2 and H-CDR3, wherein: H-CDR1 comprises the sequence NYDIS [SEQ ID NO:22] (18E12 H-CDR1); H-CDR2 comprises the sequence VIWTSGGTNYNSAFMS [SEQ ID NO:23] (18E12 H-CDR2); and H-CDR3 comprises the sequence GDGNFYLYNFDY [SEQ ID NO:24] (18E12 H-CDR3).
[0021] For example, antibodies may be selected from: (i) antibodies comprising: a VL domain comprising, consisting of, or substantially consisting of the following sequences: QSPASLAVSLGQRATISCRASESVDSFGNSFMHWYQQKAGQPPKSSIYRAANLESGIPARFSGSGSRTDFTLTINPVEADDVATYFCQQSYEDPWTFGGGTKLGNQ[SEQ ID NO:1](3C10VL); and a VH domain comprising, consisting of, or substantially consisting of the following sequences: LVKPGGSLKLSCVASGFTFSSYAMSWVRQTPEKRLEWVASISSGGTTYYPDNVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCARGYYDYHYWGQGTTLTVSS[SEQ ID NO:2](3C10VL); and a VH domain comprising, consisting of, or substantially consisting of the following sequences: LVKPGGSLKLSCVASGFTFSSYAMSWVRQTPEKRLEWVASISSGGTTYYPDNVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCARGYYDYHYWGQGTTLTVSS[SEQ ID NO:2](3C10VL). (ii) An antibody comprising: an L domain comprising, consisting of, or substantially consisting of the following sequences: QSPASLAVSLGQRATISCRASESVDSYVNSFLHWYQQKPGQPPKLLIYRASNLQSGIPARFSGSGSRTDFTLTINPVEADDVATYCCQQSNEDPTTFGGGTKLEIK[SEQ ID NO:3](28C5 VL); and a VH domain comprising, consisting of, or substantially consisting of the following sequences: LQQSGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNRLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCVRGLRFAYWGQGTLVTVSA[SEQ ID NO:4](28C5 VL); and a VH domain comprising, consisting of, or substantially consisting of the following sequences: LQQSGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNRLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCVRGLRFAYWGQGTLVTVSA[SEQ ID NO:4](28C5 (VH); and (iii) antibodies comprising: a VL domain comprising, consisting of, or substantially consisting of the following sequence: QTPSSLSASLGDRVTISCRASQDIKNYLNWYQQPGGTVKVLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQRGDTLPWTFGGGTKLEIK[SEQ ID NO:5](18E12 VL);The antibody contains, is composed of, or is substantially composed of the following sequence: LESGPGLVAPSQSLSITCTVSGFSLTNYDISWIRQPPGKGLEWLGVIWTSGGTNYNSAFMSRLSITKDNSESQVFLKMNGLQTDDTGIYYCVRGDGNFYLYNFDYWGQGTTLTVSS [SEQ ID NO:6] (18E12 VH). In a particular embodiment, the antibody is humanized or chimeric. In one example, the antibody comprises a light chain and a heavy chain, wherein: the light chain comprises the amino acid sequence: METDTILLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCRASESVDSYVNSFLHWYQQKPGQPPKLLIYRASNLQSGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC[SEQ ID] NO:25]; and the heavy chain contains the amino acid sequence: MKVLSLLYLLTAIPGILSDVQLQQSGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNRLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQL NSVTTEDTATYYCVRGLRFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKP SNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK[SEQ ID NO:26]. In a specific example, the antibody is an IC14 antibody. ;
[0022] In the above methods, acute neuroinflammatory injury can be selected from, for example, stroke (e.g., ischemic stroke or hemorrhagic stroke), hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage, and cerebral hemorrhage.
[0023] This article also provides the use of CD14 antagonist antibodies in the preparation of medicaments for the treatment of acute neuroinflammatory injuries (such as stroke, such as ischemic or hemorrhagic stroke, hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage, or cerebral hemorrhage) in human subjects, wherein the antibody is administered to the subject up to 48 hours after the injury.
[0024] On the other hand, the use of CD14 antagonist antibodies in the preparation of medicaments for treating acute neuroinflammatory injuries (e.g., stroke, such as ischemic or hemorrhagic stroke, hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage, or cerebral hemorrhage) in human subjects is provided, wherein the medicament is formulated for systemic administration to the subject, and wherein the medicament does not contain any additional active agent. In one embodiment, the medicament is administered to the subject at most 48 hours after the injury.
[0025] Another aspect of this disclosure provides the use of a CD14 antagonist antibody in the preparation of a medicament for treating acute neuroinflammatory injury in human subjects, wherein the medicament is administered to the subject in a single dose. In one embodiment, the medicament is administered to the subject at most 48 hours after the injury.
[0026] In another aspect, the present invention provides the use of a CD14 antagonist antibody in the preparation of a medicament for use in human subjects to treat acute neuroinflammatory injuries (e.g., stroke, such as ischemic or hemorrhagic stroke, hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage, or cerebral hemorrhage), wherein the antibody is selected from: (i) antibodies comprising: a) an antibody VL domain or an antigen-binding fragment thereof comprising L-CDR1, L-CDR2, and L-CDR3, wherein: L-CDR1 comprises the sequence RASESVDSFGNSFMH [SEQ ID NO:7] (3C10 L-CDR1); L-CDR2 comprises the sequence RAANLES [SEQ ID NO:8] (3C10 L-CDR2); and L-CDR3 comprises the sequence QQSYEDPWT [SEQ ID NO:9] (3C10 L-CDR1). (i) antibodies comprising: (a) the VH domain of H-CDR1, H-CDR2, and H-CDR3 or an antigen-binding fragment thereof, wherein: H-CDR1 comprises the sequence SYAMS [SEQ ID NO:10] (3C10 H-CDR1); H-CDR2 comprises the sequence SISSGGTTYYPDNVKG [SEQ ID NO:11] (3C10 H-CDR2); and H-CDR3 comprises the sequence GYYDYHY [SEQ ID NO:12] (3C10 H-CDR3); (ii) antibodies comprising: (a) the VL domain of L-CDR1, L-CDR2, and L-CDR3 or an antigen-binding fragment thereof, wherein: L-CDR1 comprises the sequence RASESVDSYVNSFLH [SEQ ID NO:13] (28C5 L-CDR1); L-CDR2 comprises the sequence RASNLQS [SEQ ID NO:14] (28C5 L-CDR1); and (b) the antibody comprising the sequence RASNLQS [SEQ ID NO:14] (28C5 L-CDR3). L-CDR2); and L-CDR3 contains the sequence QQSNEDPTT [SEQ ID NO:15] (28C5 L-CDR3); and b) an antibody VH domain or an antigen-binding fragment thereof containing H-CDR1, H-CDR2 and H-CDR3, wherein: H-CDR1 contains the sequence SDSAWN [SEQ ID NO:16] (28C5 H-CDR1); H-CDR2 contains the sequence YISYSGSTSYNPSLKS [SEQ ID NO:17] (28C5 H-CDR2); and H-CDR3 contains the sequence GLRFAY [SEQ ID NO:18] (28C5 H-CDR3); and (iii) an antibody containing: a) an antibody VL domain or an antigen-binding fragment thereof containing L-CDR1, L-CDR2 and L-CDR3, wherein: L-CDR1 contains the sequence RASQDIKNYLN [SEQ ID NO:19] (18E12). L-CDR1);L-CDR2 comprises the sequence YTSRLHS [SEQ ID NO:20] (18E12 L-CDR2); and L-CDR3 comprises the sequence QRGDTLPWT [SEQ ID NO:21] (18E12 L-CDR3); and b) an antibody VH domain or antigen-binding fragment thereof comprising H-CDR1, H-CDR2, and H-CDR3, wherein: H-CDR1 comprises the sequence NYDIS [SEQ ID NO:22] (18E12 H-CDR1); H-CDR2 comprises the sequence VIWTSGGTNYNSAFMS [SEQ ID NO:23] (18E12 H-CDR2); and H-CDR3 comprises the sequence GDGNFYLYNFDY [SEQ ID NO:24] (18E12 H-CDR3). In one embodiment, the drug is administered to the subject at most 48 hours after injury.
[0027] In one example of the use of this disclosure, the antibody comprises a light chain and a heavy chain, wherein: the light chain comprises the amino acid sequence: METDTILLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCRASESVDSYVNSFLHWYQQKPGQPPKLLIYRASNLQSGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC[SEQ ID] NO:25]; and the heavy chain contains the amino acid sequence: MKVLSLLYLLTAIPGILSDVQLQQSGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNRLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQL NSVTTEDTATYYCVRGLRFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKP SNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK[SEQ ID NO:26]. In a specific example, the antibody is an IC14 antibody.
[0028] In some embodiments of the uses described above, the drug is administered to the subject at most 12, 18, or 24 hours after injury. In specific instances, the drug is administered to the subject between 2 and 48 hours, 4 and 48 hours, 6 and 48 hours, 2 and 24 hours, 4 and 24 hours, 6 and 24 hours, 2 and 18 hours, 4 and 18 hours, 6 and 18 hours, 2 and 12 hours, 4 and 12 hours, or 6 and 12 hours. In another instance, the drug is administered as a single dose. Brief description of the attached diagram
[0030] This document describes embodiments of the disclosure by way of example only, with reference to the following figures.
[0031] Figure 1 This study demonstrates how anti-CD14 antibodies block LPS-dependent cytokine production. (A) Human microglia (from a single donor) pretreated with IC14 showed reduced TNFα in response to LPS stimulation. (B) Human peripheral blood mononuclear cells pretreated with IC14 showed a dose-dependent reduction in IL-6 in response to LPS stimulation. (C) Mouse RAW264.7 cells pretreated with anti-CD14 biG53 mAb or its F(Ab')2 showed a dose-dependent reduction in TNFα in response to LPS stimulation.
[0032] Figure 2 This is a graphical representation of the effects of antiCD14 treatment, administered as a single dose 6 hours after stroke or at daily doses over 7 days, on functional decline in mice. The effects of antiCD14 F(Ab')2 treatment on (A) body torsion, forelimb flexion, coat condition, weight loss, and vocalization; ability to remain suspended on a string; and ability to remain on an accelerated rotarod, were evaluated from 24 hours to 7 days after 30 min of middle cerebral artery occlusion (MCAO). (A) Neurological scores used to evaluate body torsion, forelimb flexion, coat condition, weight loss, and vocalization. (B) String test results. (C) Rotarod test results. Data are presented as mean ± SEM (n = 5 / group).
[0033] Figure 3 NeuN staining is shown in five horizontal sections from the anterior to posterior part of the MCAO hindbrain of mice in (A) control mice treated with PBS and (B) mice treated with antiCD14.
[0034] Figure 4 This is a graphical representation of the quantitative infarct area in mice treated with anti-CD14 7 days after MCAO and in a control group treated with PBS.
[0035] Figure 5 This is a graphical representation of the lesion distribution area in mice treated with anti-CD14 7 days after MCAO and in the PBS control group. Invention Details
[0037] 1. Definition
[0038] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. While any methods and materials similar to or equivalent to those described herein may be used to practice or test the invention, preferred methods and materials are described. For the purposes of this invention, the following terms are defined below.
[0039] The articles “a” and “an” are used in this text to refer to one or more (i.e., at least one) grammatical objects of the article. By instance, “an element” means one or more elements.
[0040] As used in this article, “and / or” means and covers any and all possible combinations of one or more related listed items, as well as combinations that are missing when interpreted as alternatively (or).
[0041] The terms “active agent” and “therapeutic agent” are used interchangeably in this document and refer to an agent that prevents, reduces or improves at least one symptom of stroke or other acute neuroinflammatory injury.
[0042] As used in this article, “acute neuroinflammatory injury” refers to an acute brain injury associated with a harmful neuroinflammatory response, that is, an acute brain injury that leads to long-term brain damage and loss of brain function without therapeutic intervention. Illustrative examples of acute neuroinflammatory injury include stroke (e.g., ischemic stroke or hemorrhagic stroke), hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage (i.e., bleeding located beneath one of the brain's protective layers, known as the arachnoid mater, and extending into the space surrounding the brain), and cerebral hemorrhage (i.e., bleeding within the brain). Symptoms of acute neuroinflammatory injury include, but are not limited to, hemiplegia (paralysis on one side of the body); mild hemiplegia (weakness on one side of the body); facial muscle weakness; numbness; decreased sensation; altered sense of smell, taste, hearing, or vision; loss of smell, taste, hearing, or vision; ptosis (drooping eyelid); detectable oculomotor muscle weakness; reduced gag reflex; reduced swallowing ability; reduced pupillary light reactivity; reduced facial sensation; reduced balance; nystagmus; altered respiratory rate; altered heart rate; sternocleidomastoid muscle weakness with reduced or absent ability to turn the head to one side; tongue weakness; aphasia (inability to speak or understand language); apraxia (altered voluntary movement); visual field defects; memory defects; hemispatial neglect or hemispatial spatial neglect (attention deficit in the visual field and space on the side opposite to the lesion); confusion; disorientation; development of excessive behavior; anapoptosis (persistent denial of existence); dyskinesia; altered motor coordination; vertigo; imbalance; loss of consciousness; headache; and / or vomiting. The term "post-injury" as used to refer to a time period means the period following the onset of one or more initial symptoms of an acute neuroinflammatory injury. Therefore, for example, "6 hours post-injury" means 6 hours after the onset of symptoms of an acute neuroinflammatory injury. It should be understood that in cases where the neuroinflammatory injury is a stroke, "post-stroke" and "post-injury" may be used interchangeably herein.
[0043] The terms "administration concurrently," "administering concurrently," or "co-administering," etc., refer to the administration of a single composition comprising two or more agents, or the administration of various agents as individual compositions and / or via separate routes, concurrently or simultaneously, or sequentially over a sufficiently short period of time, with an effective result equivalent to that obtained when all such agents are administered as a single composition. "Simultaneously" means that the agents are administered substantially at the same time and are expected to be administered together in the same formulation. "Contemporaneously" means that the agents are administered close together in time, for example, one agent is administered approximately 1 minute before or after another to approximately 1 day. Any concurrent timing is useful. However, it is generally the case that when administered at different times, the agents will be administered within approximately 1 minute to approximately 8 hours, and suitably within less than approximately 1 hour to approximately 4 hours. When administered concurrently, the agents are suitably administered to the same site on the subject. The term "samesite" includes an exact location, but can be within a range of about 0.5 cm to about 15 cm, preferably within a range of about 0.5 cm to about 5 cm. As used herein, the term "separately" means that the agent is applied at intervals, such as intervals of about one day to several weeks or months. The agent can be applied in any order. As used herein, the term "sequentially" means that the agent is applied sequentially, such as at one or more intervals of several minutes, hours, days, or weeks. Where appropriate, the agent can be applied in a regularly repeated cycle.
[0044] The term “alone” in reference to the administration of CD14 antagonist antibodies or drugs containing CD14 antagonist antibodies means that no other active agent is administered to the subject together with the CD14 antagonist antibody or drug during the treatment of the injury (e.g., stroke), i.e., the CD14 antagonist antibody or drug containing CD14 antagonist antibody is not co-administered with another active agent.
[0045] The term "antagonist antibody" is used in the broadest sense and includes antibodies that inhibit or reduce the biological activity of the antigen (e.g., CD14) to which they bind. For example, antagonist antibodies can partially or completely block the interaction between a receptor (e.g., CD14) and a ligand (e.g., DAMP or PAMP), or can actually reduce the interaction due to tertiary structural alterations or downregulation of the receptor. Thus, CD14 antagonist antibodies include antibodies that bind to CD14 and block, inhibit, nullify, antagonize, suppress, reduce, or diminish (including significantly) CD14 agonist activity to any meaningful extent. CD14 agonist activity includes activation of downstream pathways such as Toll-like receptor (TLR) signaling pathways (e.g., TLR4 signaling pathway) and induction of the IFN-β (TRIF) pathway by an adaptor containing a TIR domain, or initiation of a cellular response to CD14 binding to a CD14 ligand (e.g., DAMP or PAMP) (e.g., production of pro-inflammatory mediators, including pro-inflammatory cytokines).
[0046] The term “antibody” as used herein is used in the broadest sense and specifically encompasses naturally occurring antibodies, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), antibody fragments, or any other antigen-binding molecules, provided they exhibit the desired immune interaction. Naturally occurring “antibodies” within this scope include immunoglobulins comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain comprises a heavy chain variable region (hereinafter referred to as VH) and a heavy chain constant region. The heavy chain constant region contains specific CH domains (e.g., CH1, CH2, and CH3). Each light chain comprises a light chain variable region (hereinafter referred to as VL) and a light chain constant region. The light chain constant region contains a domain, CL. The VH and VL regions can be further subdivided into hypervariable regions (called complementarity-determining regions (CDRs)) scattered with more conserved regions (called frame regions (FRs)). Each VH and VL contains 3 CDRs and 4 FRs, arranged in the following order from the N-terminus to the C-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system. Antibodies can be any isotype (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), subclass, or modified form (e.g., the IgG1 isotype carrying the L234A and L235A double mutation (IgG1-LALA)). Antibodies can be of any species, chimeric, humanized, or human. In other embodiments, the antibody is a homopolymeric heavy chain antibody (e.g., a camel antibody) that lacks the first constant region domain (CH1) but retains the other intact heavy chains and is capable of binding antigens via antigen-binding domains. The variable regions of the heavy and light chains in the antibody-module recognition domain (MRD) fusion will contain functional binding domains that interact with the antigen of interest.
[0047] As used herein, “variable domains” (light chain variable domain (VL), heavy chain variable domain (VH)) refer to each of the light and heavy chain domain pairs that directly participate in antibody-antigen binding. The variable light and heavy chain domains have the same general structure, and each domain contains four broadly conserved free radicals (FRs) linked by three chain derived domains (CDRs) or “hypervariates.” The FRs adopt a β-sheet conformation, and the CDRs can form loops connecting the β-sheet structures. The CDRs in each chain maintain their three-dimensional structure via the FRs and, together with the CDRs from the other chain, form the antigen-binding site.
[0048] As used herein, the term “antigen-binding moiety” refers to the amino acid residues of an antibody that are typically responsible for antigen binding, which usually contain amino acid residues from CDRs. Therefore, “amino acid residue” or “complementarity-determining region” (also known as “hypervariate region”) are used interchangeably herein to refer to the amino acid sequence of the three-dimensional loop structure of the antibody light and heavy chains that contributes to the formation of the antigen-binding site. Three CDRs are present in each variable region of the heavy and light chains, which are designated “CDR1”, “CDR2”, and “CDR3”. As used herein, the term “CDR group” refers to a group of three CDRs present in a single variable region that binds the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991)) provides not only a definitive residue numbering system applicable to any variable region of an antibody but also precise residue boundaries defining the three CDRs. These CDRs may be referred to as “Kabat…” Chothia and colleagues (Chothia and Lesk, 1987. J. Mol. Biol. 196: 901-917; Chothia et al., 1989. Nature 342: 877-883) found that, despite great diversity at the amino acid sequence level, certain sub-regions within the Kabat CDR adopt almost identical peptide skeleton architectures. These sub-regions are named “L1,” “L2,” and “L3,” or “H1,” “H2,” and “H3,” where “L” and “H” name the light chain region and the heavy chain region, respectively. These regions can be referred to as the “Chothia CDR,” which has boundaries that overlap with the Kabat CDR. Other boundaries defining CDRs that overlap with the Kabat CDR are defined by Padlan (1995. FASEB). The definitions in J.9:133-139 and MacCallum (1996. J.Mol.Biol.262(5):732-745) describe this. Other CDR boundary definitions may not strictly follow one of these systems, but will still overlap with the Kabat CDR, although they may be shortened or lengthened depending on the specific residue or group of residues or even the entire CDR, which does not significantly affect the prediction or experimental results of antigen binding.
[0049] As used herein, the term "frame region" or "FR" refers to the remaining sequence of the variable region minus the CDR. Therefore, the variable domains of the antibody's light and heavy chains, from the N-terminus to the C-terminus, contain domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. CDRs and FRs are typically determined according to the standard definitions in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, National Institutes of Health, Bethesda, Md. (1991) and / or from those residues derived from the "hypervariant loop".
[0050] As used herein, the terms “light chain variable region” (“VL”) and “heavy chain variable region” (“VH”) refer to regions or domains at the N-terminal portions of the light and heavy chains, respectively, that have different primary amino acid sequences for each antibody. The variable region of an antibody typically consists of the N-terminal domains of the light and heavy chains, as they fold together to form a three-dimensional binding site against the antigen. For example, several subtypes of VH and VL have been defined based on structural similarity, as listed in the Kabat database.
[0051] The term "chimeric antibody" refers to an antibody that contains heavy and light chain variable region sequences from one species and constant region sequences from another species, such as antibodies with mouse heavy and light chain variable regions linked to human constant regions.
[0052] The “humanized” form of non-human (e.g., rodent) antibodies is a chimeric antibody containing a minimal sequence derived from a non-human immunoglobulin. In most cases, a humanized antibody is a human immunoglobulin (recipient antibody) with the desired specificity, affinity, and / or ability, in which residues from the hypervariable region of the recipient are replaced by residues from the hypervariable region of a non-human species (donor antibody), such as mice, rats, rabbits, or non-human primates. In some cases, the framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Therefore, the FR and CDR of a humanized antibody do not need to correspond precisely to the parental (i.e., donor) sequence; for example, the donor antibody CDR or common framework can be mutagenized by substitution, insertion, and / or deletion of at least one amino acid residue such that the CDR or FR at that site does not correspond to the donor antibody or common framework. However, such mutations are generally not widespread and typically avoid “critical residues” involved in antigen binding. Typically, at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% of the humanized antibody residues will correspond to those residues in the parental FR and CDR sequences. As used herein, the term "shared frame" refers to a frame region in a shared immunoglobulin sequence. As used herein, the term "shared immunoglobulin sequence" refers to a sequence formed by the most frequently occurring amino acid (or nucleotide) in the relevant immunoglobulin sequence family (see, for example, Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, 1987)). Thus, a "shared immunoglobulin sequence" may contain one or more "shared frame regions" and / or one or more "shared CDRs". In an immunoglobulin family, each position in the shared sequence is occupied by the most frequently occurring amino acid in that position within the family. If two amino acids occur with equal frequency, either one can be included in the shared sequence. Typically, humanized antibodies will contain at least one, and usually substantially all, of the two variable domains, wherein all or substantially all of the hypervariable loops correspond to those of non-human immunoglobulins, and all or substantially all of the FRs are those of human immunoglobulin sequences. Humanized antibodies will also optionally contain at least a portion of the immunoglobulin constant region (Fc), typically a portion of a human immunoglobulin. For further details, see Jones et al., (1986. Nature 321:522-525), Riechmann et al. (1988. Nature 332:323-329), and Presta (1992. Curr. Op. Struct. Biol. 2:593-596).Humanized antibodies can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA, and IgE, and any isotypes, including but not limited to IgG1, IgG2, IgG3, and IgG4. Humanized antibodies can contain sequences from more than one class or isotype, and specific constant domains can be selected using techniques well known in the art to optimize desired effector functions. As used herein, the term "critical residue" refers to certain residues within the variable region that have a greater influence on the binding specificity and / or affinity of the antibody, particularly humanized antibodies. Critical residues include, but are not limited to, one or more of the following: residues adjacent to the CDR, potential glycosylation sites (which may be N-glycosylation sites or O-glycosylation sites), rare residues, residues capable of interacting with the antigen, residues capable of interacting with the CDR, typical residues, contact residues between the heavy chain variable region and the light chain variable region, residues within the vernier zone, and residues in the region overlapping between the Chothia definition of the variable heavy chain CDR1 and the Kabat definition of the first heavy chain frame.
[0053] As used in this paper, the "vernier" region refers to a subgroup of framework residues that can modulate the CDR structure and fine-tune the fit to the antigen, as described by Foote and Winter (1992. J. Mol. Biol. 224: 487-499). Vernier region residues form a layer beneath the CDR and may affect the structure of the CDR and antibody affinity.
[0054] As used herein, the term "typical" residue refers to a residue in a CDR or framework as defined by Chothia et al. (1987. J. Mol. Biol. 196:901-917; 1992. J. Mol. Biol. 227:799-817, both incorporated herein by reference). According to Chothia et al., the key portions of the CDRs of many antibodies, despite their great diversity at the amino acid sequence level, share a nearly identical peptide backbone profile. Each typical structure primarily specifies a set of peptide backbone twist angles of a continuous segment of amino acid residues forming a loop.
[0055] As used herein, the terms "donor" and "donor antibody" refer to an antibody that provides one or more CDRs to the "recipient antibody." In some embodiments, the donor antibody is an antibody from a different species than the antibody from which the FR is obtained or derived. In the context of humanized antibodies, the term "donor antibody" refers to a non-human antibody that provides one or more CDRs.
[0056] As used herein, the terms "recipient" and "recipient antibody" refer to an antibody that provides at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% of the amino acid sequence of one or more free radicals (FRs). In some embodiments, the term "recipient" refers to an antibody amino acid sequence that provides one or more constant regions. In other embodiments, the term "recipient" refers to an antibody amino acid sequence that provides one or more FRs and one or more constant regions. In a particular embodiment, the term "recipient" refers to a human antibody amino acid sequence that provides at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 98%, or 100% of the amino acid sequence of one or more FRs. According to this embodiment, the recipient may contain at least one, at least two, at least three, at least four, at least five, or at least ten amino acid residues that are not (or do not) present at one or more specific positions on the human antibody. The acceptor frame region and / or one or more acceptor constant regions may be derived from or obtained from germline antibody genes, mature antibody genes, functional antibodies (e.g., antibodies well known in the art, antibodies under development, or commercially available antibodies).
[0057] As used herein, the term "human antibody" is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies of the present invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutations in vivo), such as in CDRs, and particularly in CDR3. However, the term "human antibody" as used herein is not intended to include antibodies in which a germline CDR sequence derived from another mammalian species (such as a mouse) has been grafted onto a human frame sequence.
[0058] The terms “heavy chain variable region CDR1” and “H-CDR1” are used interchangeably, as are the terms “heavy chain variable region CDR2” and “H-CDR2”, “heavy chain variable region CDR3” and “H-CDR3”; the terms “light chain variable region CDR1” and “L-CDR1”, “light chain variable region CDR2” and “L-CDR2”, and “light chain variable region CDR3” and “L-CDR3” for antibody fragments also apply. Throughout this specification, unless otherwise specified, the complementarity-determining region (“CDR”) is defined according to the Kabat definition. The Kabat definition is a standard used for numbering residues in antibodies and is commonly used to identify CDR regions (Kabat et al., (1991), 5th edition, NIH Publication No. 91-3242).
[0059] Antigen binding can occur via a “fragment” or “antigen-binding fragment” of a complete antibody. These terms are used interchangeably herein. Examples of binding fragments included within the term “antibody fragment” of an antibody include Fab fragments, monovalent fragments consisting of VL, VH, CL, and CH1 domains; F(ab')2 fragments, bivalent fragments comprising two Fab fragments linked at the hinge region by disulfide bonds; Fd fragments consisting of VH and CH1 domains; Fv fragments consisting of VL and VH domains of an antibody single arm; single-domain antibody (dAb) fragments consisting of a VH domain (Ward et al., 1989. Nature 341:544-546); and isolated complementarity-determining regions (CDRs). In a particular embodiment, the antibody of this disclosure is an antigen-binding fragment lacking all or part of the Fc region.
[0060] A “single-chain variable fragment (scFv)” is a single protein chain in which the VL and VH regions pair to form a monovalent molecule (referred to as a single-chain Fv (scFv); see, for example, Bird et al., 1988. Science 242:423-426; and Huston et al., 1988. Proc. Natl. Acad. Sci. 85:5879-5883). Although the VL and VH domains are encoded by separate genes, they can be linked together using recombinant methods via artificial peptide linkers, allowing them to be made into a single protein chain. Such single-chain antibodies comprise one or more antigen-binding moieties. These antibody fragments can be obtained using conventional techniques known to those skilled in the art, and the utility of the fragments can be screened in the same manner as for intact antibodies.
[0061] As used herein, the term "monoclonal antibody" and the abbreviations "MAb" and "mAb" refer to antibodies obtained from a largely homogeneous population of antibodies; that is, the individual antibodies constituting the population are identical, except for a possible small number of naturally occurring mutations. Monoclonal antibodies are highly specific, targeting a single antigen. Furthermore, each mAb targets a single determinant on an antigen, unlike polyclonal antibody products, which typically comprise different antibodies targeting different determinants (epitopes). The modifier "monoclonal" should not be interpreted as requiring the antibody to be produced by any particular method. For example, monoclonal antibodies can be produced from a single clone of antibody-producing cells (including hybridomas). The term "hybridoma" generally refers to a cell fusion product between cultured neoplastic lymphocytes and sensitized B- or T- lymphocytes that expresses parental cell-specific immune potential.
[0062] An antibody that “binds” to an antigen of interest (e.g., CD14) is an antibody that binds to the antigen with sufficient affinity so that it can be used as a therapeutic agent targeting cells or tissues expressing that antigen, and does not significantly cross-react with other proteins. In such embodiments, the degree of binding of the antibody to a “non-target” protein will be less than about 10% of the binding of the antibody, oligopeptide, or other organic molecule to its specific target protein, as determined, for example, by fluorescence activated cell sorting (FACS) analysis, enzyme-linked immunosorbent assay (ELISA), immunoprecipitation, or radioimmunoprecipitation (RIA). Thus, antibodies antagonizing CD14 suitably inhibit or reduce the production of pro-inflammatory mediators, including pro-inflammatory cytokines / chemokines. Regarding the binding of an antibody to a target molecule, the term “specific binding” to a specific polypeptide or epitope on a specific polypeptide target, or “specific binding to a specific polypeptide or epitope on a specific polypeptide target,” or “specific” for a specific polypeptide or epitope on a specific polypeptide target, means a binding that is measurably different from non-specific interactions. For example, specific binding can be measured by comparing the binding of a identified molecule to the binding of a control molecule, which is typically a molecule with a similar structure that does not have binding activity. For example, specific binding can be determined by competition with a control molecule similar to the target, such as an excess of the unlabeled target. In this case, if the binding of the labeled target to the probe is competitively inhibited by the excess of the unlabeled target, it indicates specific binding. The specific region of an antigen that an antibody binds to is often called an "epitaph." The term "epitaph" broadly includes sites on an antigen that are specifically recognized by an antibody or T-cell receptor or otherwise interact with a molecule. Typically, epitopes are groups of active surfaces of molecules, such as amino acids or carbohydrate or sugar side chains, and often have specific three-dimensional structural features, as well as specific charge features. As those skilled in the art will understand, almost anything an antibody can specifically bind to can be an epitope.
[0063] Throughout this specification, unless the context otherwise requires, the terms “comprise,” “comprises,” and “comprising” will be understood to imply inclusion of a stated step or element or group of steps or elements, but do not exclude any other step or element or group of steps or elements. Therefore, the use of the term “comprising” indicates that the listed elements are necessary or required, but other elements are optional and may or may not be present. “consisting of” means including and limited to anything following the phrase “consisting of.” Therefore, the phrase “consisting of” indicates that the listed elements are necessary or required, and no other elements may be present. “consisting essentially of” means including any element listed following that phrase, and is limited to other elements that do not interfere with or contribute to the activity or function specified in this disclosure of the listed elements. Therefore, the phrase “consisting essentially of…” indicates that the listed elements are necessary or required, but other elements are optional and may or may not be present, depending on whether they affect the activity or function of the listed elements.
[0064] In the context of a therapeutic condition, an "effective dose" refers to the amount of a drug or composition (as a single dose or as part of a series) administered to an individual requiring this treatment or prevention that is effective in preventing the onset of symptoms of the condition, controlling (holding incheck) such symptoms of the condition, and / or treating existing symptoms of the condition. The effective dose will vary depending on the individual's age, health and physical condition, the severity of disease symptoms, the individual's taxonomic group, the formulation of the composition, evaluation of the medical condition, and other relevant factors. The optimal dosing schedule can be calculated based on measurements of drug accumulation in the subject. The optimal dose can vary depending on its relative efficacy in individual subjects and can generally be estimated based on EC50 values found to be effective in in vitro and in vivo animal models. The optimal dose, method of administration, and repetition rate can be readily determined by a person of ordinary skill. It is expected that the dose will fall within a relatively wide range that can be determined through routine testing.
[0065] As used herein, the term "immune cell" refers to cells belonging to the immune system. Immune cells include hematopoietic cells, such as, but not limited to, T lymphocytes (T cells), B lymphocytes (B cells), natural killer (NK) cells, granulocytes, neutrophils, macrophages, monocytes, dendritic cells, and specialized forms of any of the aforementioned cells, such as plasmacytoid dendritic cells, Langerhans cells, plasma cells, natural killer T (NKT) cells, T helper cells, and cytotoxic T lymphocytes (CTLs).
[0066] As used herein, the terms “inhibit,” “inhibiting,” “decrease,” or “decreasing,” related to the “production of pro-inflammatory mediators” in cells, refer to at least a small but measurable reduction in the level or amount of pro-inflammatory mediators produced by peripheral cells. In embodiments, the production of pro-inflammatory mediators in cells is inhibited or reduced by at least 20% compared to an untreated control; in more embodiments, the inhibition or reduction is at least 50%; in still more embodiments, the inhibition or reduction is at least 70%; and in some embodiments, the inhibition or reduction is at least 80%. In in vivo embodiments, this reduction in the production of pro-inflammatory mediators mitigates the detrimental effects of the inflammatory mediator cascade.
[0067] The efficacy of CD14 antagonist antibodies in inhibiting or reducing the production of pro-inflammatory mediators in peripheral cells can be evaluated using appropriate in vitro assays (e.g., ELISA, RT-PCR). For example, the levels of intracellularly acquired cytokine mRNA can be measured using competitive RT-PCR, and the levels of expressed cytokines released from cells can be measured by sandwich ELISA, for example, using one or more monoclonal antibodies that specifically bind to a particular cytokine. In vivo screening can also be performed using procedures well known in the art. For example, CD14 antagonist antibodies are administered to an animal model (e.g., a mouse) and blood is collected to evaluate the levels of multiple cytokines. Those skilled in the art will be proficient in the techniques that can be used to measure cytokine production. Based on the results, an appropriate dose range and systemic route of administration can also be determined.
[0068] As used in this article, the term "ischemia" refers to insufficient or absent blood flow to a body part caused by the contraction or blockage of blood vessels that supply blood.
[0069] The term "hypoxic-ischemic brain injury" refers to an absolute or relative insufficiency of the brain's oxygen or blood supply, leading to damage or dysfunction of brain tissue. Hypoxic-ischemic brain injury can result from a variety of diseases, lesions, or injuries, including, for example, cardiac arrest, ischemic stroke, head trauma, asphyxia, or poisoning (such as carbon monoxide poisoning or drug overdose). Severe or prolonged cerebral ischemia can lead to loss of consciousness, brain damage, or death mediated by the ischemic cascade (e.g., neuronal damage).
[0070] "Separate" means that the substance is largely or essentially not contained in the components that usually accompany it in its natural state.
[0071] As used in this article, the term "ligand" refers to any molecule that can bind to a receptor.
[0072] "Pharmaceutically acceptable carriers" means drug delivery systems that include substances that are not biologically or otherwise undesirable; that is, substances that can be administered to subjects together with a selected active agent without causing any or significant adverse reactions. Carriers may include excipients and other additives such as diluents, detergents, colorants, wetting agents or emulsifiers, pH buffers, preservatives, transfection agents, etc.
[0073] Similarly, a “pharmaceutically acceptable” salt, ester, amide, prodrug, or derivative of a compound as described herein is one that is not biologically or otherwise undesirable.
[0074] The terms “polynucleotide,” “genetic material,” “genetic form,” “nucleic acid,” and “nucleotide sequence” include RNA, cDNA, genomic DNA, synthetic forms, and mixed polymers (both sense and antisense strands), and may be chemically or biochemically modified or may contain non-natural or derived nucleotide bases, as will be readily understood by those skilled in the art.
[0075] The term "pro-inflammatory mediator" refers to immunomodulators that promote inflammation. Such agents include cytokines such as chemokines, interleukins (ILs), lymphokines, and tumor necrosis factor (TNF), as well as growth factors. In a particular embodiment, the pro-inflammatory mediator is "pro-inflammatory cytokines." Typically, pro-inflammatory cytokines include IL-1α, IL-1β, IL-6, and TNF-α, which are primarily responsible for the early response. Other pro-inflammatory mediators include LIF, IFN-γ, IFN-β, IFN-α, OSM, CNTF, TGF-β, GM-CSF, TWEAK, IL-11, IL-12, IL-15, IL-17, IL-18, IL-19, IL-20, IL-8, IL-16, IL-22, IL-23, IL-31, and IL-32 (Tato et al., 2008. Cell 132:900; Cell 132:500, Cell 132:324). Pro-inflammatory mediators can act as endogenous pyrogens (IL-1, IL-6, IL-17, TNF-α), upregulate the synthesis of secondary mediators and pro-inflammatory cytokines in both macrophages and mesenchymal cells (including fibroblasts, epithelial cells, and endothelial cells), stimulate the production of acute-phase proteins, or attract inflammatory cells. In certain embodiments, the term "pro-inflammatory cytokines" refers to TNF-α, IL-1α, IL-6, IFNβ, IL-1β, IL-8, IL-17, and IL-18.
[0076] As used herein, “stroke” refers to one or more losses of brain function (often rapidly developing) due to a disruption of the blood supply to the brain or brainstem. This disruption may be caused by ischemia (lack of blood flow), such as thrombosis or embolism, or by hemorrhage. In some cases, the loss of brain function is accompanied by the death of neurons. In one instance, a stroke is caused by a disturbance or loss of blood flow to the brain or its regions. A stroke is a neurological deficit caused by cerebrovascular factors that lasts longer than 24 hours or is interrupted by death within 24 hours (as defined by the World Health Organization). Symptoms of stroke include hemiplegia (paralysis on one side of the body); mild hemiplegia (weakness on one side of the body); facial muscle weakness; numbness; decreased sensation; altered sense of smell, taste, hearing, or vision; loss of smell, taste, hearing, or vision; ptosis (drooping eyelid); detectable weakness of the extraocular muscles; reduced gag reflex; reduced swallowing ability; reduced pupillary light reactivity; reduced facial sensation; reduced balance; nystagmus; altered respiratory rate; altered heart rate; sternocleidomastoid muscle weakness with reduced or absent ability to turn the head to one side; tongue weakness; aphasia (inability to speak or understand language); apraxia (altered voluntary movement); visual field defects; memory defects; hemispatial neglect or hemispatial spatial neglect (attention deficit in the visual field and space on the side opposite to the lesion); confusion; disorientation; development of excessive behavior; anapoptosis (persistent denial of existence); difficulty walking; altered motor coordination; dizziness; imbalance; loss of consciousness; headache; and / or vomiting. The term "post-stroke" refers to the period following the onset of one or more initial symptoms of a stroke. Therefore, for example, "6 hours post-stroke" means 6 hours after the onset of stroke symptoms.
[0077] As used herein, the terms “systemic administration,” “administered systemically,” or “systemically administered” mean the introduction of an agent outside the central nervous system of a subject. Systemic administration includes any route of administration other than direct administration to the spine or brain. Therefore, it is evident that intrathecal and epidural administration, as well as intracranial injection or implantation, are not within the scope of the terms “systemic administration,” “administered systemically,” or “systemically administered.” Agents (e.g., antibodies) or pharmaceutical compositions described herein can be administered systemically in any acceptable form, such as tablets, liquids, capsules, powders, etc.; by intravenous, intraperitoneal, intramuscular, subcutaneous, or parenteral injection; by transdermal diffusion or electrophoresis; and by a micropump or other implanted extended-release device or formulation. According to some embodiments, systemic administration is carried out via a route selected from the group consisting of intraperitoneal, intravenous, subcutaneous, and intranasal administration and combinations thereof.
[0078] In this document, "single-dose" CD14 antagonist antibody means that only one dose of the antibody is administered to the subject following an acute neuritis injury, such as via a single bolus injection or a single discrete infusion. In the event of further acute neuritis injury, a single dose of the antibody may be administered to the subject against that further acute neuritis injury. Therefore, "single-dose" means that the subject receives only one dose of the antibody in each instance of acute neuritis injury.
[0079] In this document, the terms “subject,” “patient,” and “individual,” which are used interchangeably, refer to any subject who has suffered acute neuroinflammatory injury, particularly vertebrate subjects, and even more particularly mammalian subjects (e.g., humans).
[0080] The term “traumatic brain injury” or “TBI” refers to brain injury caused by external physical trauma. Non-limiting examples of events that can lead to TBI include falls, vehicle collisions, sports collisions, and fights. The term includes both mild and severe TBI, including closed head injuries, concussions or contusions, and penetrating head injuries.
[0081] As used herein, the terms “treatment,” “treating,” etc., refer to achieving the desired pharmacological and / or physiological effect in a subject requiring treatment, i.e., a subject who has suffered acute neuroinflammatory injury. “Treatment” means: improvement or prevention of one or more symptoms of acute neuroinflammatory injury; improvement or prevention of neuronal damage or neurological deficits; and / or improvement or prolongation of quality of life. References to “treatment,” “treat,” or “treating” do not necessarily mean reversing or preventing any or all symptoms of acute neuroinflammatory injury, or reversing or preventing neuronal damage or neurological deficits. For example, a subject may eventually suffer from long-term neurological deficits, but with reduced deficits and / or improved quality of life compared to an untreated level of deficit or quality of life.
[0082] As used herein, the term "at most" in relation to the time period following injury or stroke for administering CD14 antagonist antibodies means that no CD14 antagonist antibody will be administered to the subject beyond that time period during treatment of the injury (e.g., stroke). Therefore, for example, stating "at most 48 hours post-injury" for administering CD14 antagonist antibodies to the subject means that the CD14 antagonist antibody may be administered to the subject at any time between 0 and 48 hours post-injury, but never after 48 hours. Administration may include one or more doses of CD14 antagonist antibody, but no dose will be administered after the specified time period, such as 48 hours post-injury. However, it should be understood that if the subject subsequently suffers further acute neuroinflammatory injury, the CD14 antagonist antibody may be administered to the subject within the time period defined for that further acute neuroinflammatory injury.
[0083] Unless otherwise expressly stated, each implementation described herein will be modified in detail as necessary to suit each and every implementation.
[0084] 2. Compositions and methods for treating inflammatory neurological injuries
[0085] This disclosure provides methods, uses, and compositions for treating acute neuroinflammatory injuries, including CD14 antagonist antibodies.
[0086] 2.1 CD14 antagonist antibody
[0087] This disclosure contemplates any CD14 antagonist antibody that binds to CD14 (e.g., mCD14 or sCD14) and blocks the binding of DAMP or PAMP to CD14 and / or binds to CD14 and inhibits or reduces CD14 agonist-mediated responses leading to the production of pro-inflammatory mediators (including the production of pro-inflammatory cytokines). In some embodiments, the CD14 antagonist antibody of the present invention inhibits the binding of a CD14 agonist (suitably DAMP or PAMP) to CD14, thereby inhibiting or reducing the production of pro-inflammatory cytokines. In illustrative examples of this type, CD14 antagonist antibodies are selected from 3C10 antibodies (van Voohris et al., 1983. J. Exp. Med. 158: 126-145; Juan et al., 1995. J. Biol. Chem. 270(29): 17237-17242) that bind epitopes contained in at least a portion of the region of amino acids 57 to 64 of CD14, MEM-18 antibodies (Bazil et al., 1986. Eur. J. Immunol. 16(12): 1583-1589; Juan et al., 1995. J. Biol. Chem. 270(10): 5219-5224) that bind epitopes contained in at least a portion of the region of amino acids 57 to 64 of CD14, and 4C1 antibodies (Adachi et al., 1999. J. Endotoxin). Res. 5:139–146; Tasaka et al., 2003. Am. J. Respir. Cell. Mol. Biol.; 2003. 29(2):252-258), and antibodies that inhibit LPS binding and suppress the production of pro-inflammatory cytokines, such as 28C5 and 23G4, and antibodies that partially inhibit LPS binding and suppress the production of pro-inflammatory cytokines, such as 18E12 (US Patent Nos. 5,820,858, 6,444,206, and 7,326,569 to Leturcq et al.). In some embodiments, the CD14 antagonist antibodies of this disclosure inhibit the binding of CD14 to TLRs such as TLR4, thereby blocking a CD14 agonist-mediated response, exemplary examples of which include the F1024 antibody disclosed in International Publication WO2002 / 42333. Each of the above references relating to CD14 antagonist antibodies is incorporated herein by reference in its entirety. CD14 antagonist antibodies can be full-length immunoglobulin antibodies or antigen-binding fragments of intact antibodies. Representative examples include Fab fragments, F(ab')2 fragments, Fd fragments composed of VH and CH1 domains, Fv fragments composed of VL and VH domains of the antibody arm, single-domain antibody (dAb) fragments composed of VH domains (Ward et al., 1989 Nature 341:544-546), and isolated CDRs.Appropriately, CD14 antagonist antibodies are chimeric, humanized, or human antibodies.
[0088] In some embodiments, the CD14 antagonist antibody is selected from the antibody disclosed in U.S. Patent No. 5,820,858.
[0089] (1) Contains the following antibodies:
[0090] VL domains containing, consisting of, or substantially consisting of the following sequences: QSPASLAVSLGQRATISCRASESVDSFGNSFMHWYQQKAGQPPKSSIYRAANLESGIPARFSGSGSRTDFTLTINPVEADDVATYFCQQSYEDPWTFGGGTKLGNQ[SEQ ID NO:1](3C10 VL); and
[0091] VH domain containing, consisting of, or substantially consisting of the following sequences: LVKPGGSLKLSCVASGFTFSSYAMSWVRQTPEKRLEWVASISSGGTTYYPDNVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCARGYYDYHYWGQGTTLTVSS [SEQ ID NO:2](3C10 VH);
[0092] (2) Contains the following antibodies:
[0093] VL domains containing, consisting of, or substantially consisting of the following sequences: QSPASLAVSLGQRATISCRASESVDSYVNSFLHWYQQKPGQPPKLLIYRASNLQSGIPARFSGSGSRTDFTLTINPVEADDVATYCCQQSNEDPTTFGGGTKLEIK[SEQ ID NO:3](28C5 VL); and
[0094] VH domains containing, consisting of, or substantially consisting of the following sequences: LQQSGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNRLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCVRGLRFAYWGQGTLVTVSA [SEQ ID NO:4](28C5 VH); and
[0095] (3) Contains the following antibodies:
[0096] VL domains containing, consisting of, or substantially consisting of the following sequences: QTPSSLSASLGDRVTISCRASQDIKNYLNWYQQPGGTVKVLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQRGDTLPWTFGGGTKLEIK[SEQ ID NO:5](18E12 VL); and
[0097] VH domains containing, consisting of, or substantially consisting of the following sequences: LESGPGLVAPSQSLSITCTVSGFSLTNYDISWIRQPPGKGLEWLGVIWTSGGTNYNSAFMSRLSITKDNSESQVFLKMNGLQTDDTGIYYCVRGDGNFYLYNFDYWGQGTTLTVSS[SEQ ID NO:6](18E12 VH);
[0098] Antibodies containing the VL and VH CDR sequences of the above antibodies were also considered, with representative implementation schemes including:
[0099] (1) An antibody comprising: a) an antibody VL domain or an antigen-binding fragment thereof comprising L-CDR1, L-CDR2 and L-CDR3, wherein: L-CDR1 comprises the sequence RASESVDSFGNSFMH [SEQ ID NO:7] (3C10 L-CDR1); L-CDR2 comprises the sequence RAANLES [SEQ ID NO:8] (3C10 L-CDR2); and L-CDR3 comprises the sequence QQSYEDPWT [SEQ ID NO:9] (3C10 L-CDR3); and b) an antibody VH domain or an antigen-binding fragment thereof comprising H-CDR1, H-CDR2 and H-CDR3, wherein: H-CDR1 comprises the sequence SYAMS [SEQ ID NO:10] (3C10 H-CDR1); H-CDR2 comprises the sequence SISSGGTTYYPDNVKG [SEQ ID NO:11] (3C10 H-CDR1); H-CDR2); and H-CDR3 contains the sequence GYYDYHY[SEQ IDNO:12](3C10 H-CDR3);
[0100] (2) Antibodies comprising: a) antibody VL domains or antigen-binding fragments thereof comprising L-CDR1, L-CDR2 and L-CDR3, wherein: L-CDR1 comprises the sequence RASESVDSYVNSFLH [SEQ ID NO:13] (28C5 L-CDR1); L-CDR2 comprises the sequence RASNLQS [SEQ ID NO:14] (28C5 L-CDR2); and L-CDR3 comprises the sequence QQSNEDPTT [SEQ ID NO:15] (28C5 L-CDR3); and b) antibody VH domains or antigen-binding fragments thereof comprising H-CDR1, H-CDR2 and H-CDR3, wherein: H-CDR1 comprises the sequence SDSAWN [SEQ ID NO:16] (28C5 H-CDR1); H-CDR2 comprises the sequence YISYSGSTSYNPSLKS [SEQ ID NO:17] (28C5 H-CDR2); and H-CDR3 contains the sequence GLRFAY [SEQ ID NO: 18] (28C5 H-CDR3); and
[0101] (3) Antibodies comprising: a) antibody VL domains or antigen-binding fragments thereof comprising L-CDR1, L-CDR2 and L-CDR3, wherein: L-CDR1 comprises the sequence RASQDIKNYLN [SEQ ID NO:19] (18E12 L-CDR1); L-CDR2 comprises the sequence YTSRLHS [SEQ ID NO:20] (18E12 L-CDR2); and L-CDR3 comprises the sequence QRGDTLPWT [SEQ ID NO:21] (18E12 L-CDR3); and b) antibody VH domains or antigen-binding fragments thereof comprising H-CDR1, H-CDR2 and H-CDR3, wherein: H-CDR1 comprises the sequence NYDIS [SEQ ID NO:22] (18E12 H-CDR1); H-CDR2 comprises the sequence VIWTSGGTNYNSAFMS [SEQ ID NO:23] (18E12 H-CDR1). H-CDR2); and H-CDR3 contains the sequence GDGNFYLYNFDY[SEQ ID NO:24](18E12 H-CDR3).
[0102] In some implementations, the CD14 antagonist antibody is humanized. In illustrative examples of this type, the humanized CD14 antagonist antibody suitably comprises a donor CDR set corresponding to the CD14 antagonist antibody (e.g., one of the CD14 antagonist antibodies described above) and a human recipient frame. The human recipient frame may contain at least one amino acid substitution at key residues selected from the group consisting of: residues adjacent to the CDR; glycosylation site residues; rare residues; typical residues; contact residues between the heavy chain variable region and the light chain variable region; residues within the vernier region; and residues in the region overlapping between the VH CDR1 defined by Chothia and the first heavy chain frame defined by Kabat. Techniques for generating humanized mAbs are well known in the art (see, for example, Jones et al., 1986. Nature 321:522-525; Riechmann et al., 1988. Nature 332:323-329; Verhoeyen et al., 1988. Science 239:1534-1536; Carter et al., 1992. Proc. Natl. Acad. Sci. USA 89:4285-4289; Sandhu, JS., 1992. Crit. Rev. Biotech. 12:437-462; and Singer et al., 1993. J. Immunol. 150:2844-2857). Chimeric or murine monoclonal antibodies can be humanized by transferring murine CDRs from the heavy and light chain variable chains of murine immunoglobulins to the corresponding variable domains of human antibodies. In chimeric monoclonal antibodies, the mouse framework region (FR) is also substituted with a human FR sequence. Since simply transferring the mouse CDR into the human FR often results in decreased or even lost antibody affinity, further modifications may be necessary to restore the original affinity of the mouse antibody. This can be achieved by replacing one or more human residues in the FR region with their mouse counterparts to obtain antibodies with good binding affinity to their epitopes. See, for example, Tempest et al. (1991. Biotehnology 9:266-271) and Verhoeyen et al. (1988, ibid.). Typically, those human FR amino acid residues that differ from their mouse counterparts and are located near or in contact with one or more CDR amino acid residues are candidates for substitution.
[0103] In a preferred embodiment, the CD14 antagonist antibody is an IC14 antibody (Axtelle et al., 2001. J. Endotoxin Res. 7:310-314; and U.S. Patent Application No. 2006 / 0121574, which is incorporated herein by reference in its entirety) or an antigen-binding fragment thereof. The IC14 antibody is a chimeric (mouse / human) monoclonal antibody that specifically binds to human CD14. The mouse parent of this antibody is the aforementioned 28C5 (see, Leturcq et al., Patent Applications Nos. 5,820,858, 6,444,206, and 7,326,569, and Leturcq et al., 1996. J. Clin. Invest. 98:1533-1538). The IC14 antibody comprises a VL domain and a VH domain, wherein:
[0104] The VL domain contains the amino acid sequence: METDTILLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCRASESVDSYVNSFLHWYQQKPGQPPKLLIYRASNLQSGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQ SNEDPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC[SEQ ID NO:25]; and
[0105] The VH domain contains the amino acid sequence: MKVLSLLYLLTAIPGILSDVQLQQSGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNRLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTT EDTATYYCVRGLRFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNT KVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK[SEQ ID NO:26].
[0106] Additional CD14 antagonist antibodies suitable for treating neuroinflammatory injuries such as stroke or ischemic brain injury can be identified by methods well known to those skilled in the art. These methods typically involve determining whether the antibody can directly antagonize CD14. For example, methods may include determining whether the antibody can inhibit or reduce the amount or agonist activity of CD14, wherein the ability to inhibit or reduce the amount or agonist activity of CD14 indicates that the antibody may be suitable for treating stroke or ischemic brain injury as described herein. In some embodiments, the antibody is contacted with CD14 or cells expressing CD14 on their surface or from nucleic acid sequences expressing CD14, suitably in the presence of a CD14 agonist such as DAMP or PAMP, wherein a reduction in the amount or agonist activity of CD14 in the presence of the agonist, compared to a control, indicates that the antibody binds to and directly antagonizes CD14. Reduction or inhibition of CD14 agonist activity includes, for example, inhibiting or reducing activation of downstream pathways such as the TLR signaling pathway (e.g., the TLR4 signaling pathway) and the TRIF pathway, or inducing cellular responses (e.g., the production of pro-inflammatory mediators including pro-inflammatory cytokines).
[0107] These methods can be performed in vivo, in vitro, or ex vivo. Specifically, the step of contacting the antibody with CD14 or with cells (e.g., immune cells) expressing CD14 on their surface can be performed in vivo, in vitro, or ex vivo. The methods can be performed in cell-based or cell-free systems. For example, a method may include contacting cells expressing CD14 on their surface with an antibody and determining whether the contact between the cell and the antibody results in a reduction in the amount of CD14 or agonist activity. In such cell-based assays, CD14 and / or the antibody may be endogenous to the host cells and can be introduced into the host cells or tissues, either by inducing or allowing the expression of a construct or vector, or by stimulating or activating the expression of an endogenous gene in the cells. In such cell-based methods, the amount of CD14 activity can be evaluated in the presence or absence of the antibody to determine whether the agent is altering the amount of CD14 in the cells, such as by regulating CD14 expression in the cells or by destabilizing the intracellular CD14 protein or altering the CD14 agonist activity in the cells. A lower CD14 agonist activity or a reduced amount of CD14 on the cell surface in the presence of an antibody indicates that the antibody may be a suitable CD14 antagonist for use according to this disclosure.
[0108] In some instances, it is further determined whether the antibody lacks a substantially or detectable binding to another cellular component (suitably a CD14-binding ligand, such as a secreted one (e.g., MD2) or a CD14-binding ligand located on the cell membrane (e.g., TLR4)) to determine if the antibody is a CD14-specific antagonist. In a non-limiting instance of this type, the antibody is contacted in the presence of a CD14 agonist such as DAMP or PAMP with (1) wild-type cells (e.g., immune cells, such as macrophages) expressing CD14 on their surface, and (2) CD14-negative cells (e.g., immune cells identical to those in (1) but with a loss of function in the CD14 gene). If the antibody inhibits the CD14 agonist activity of wild-type cells but not the activity of CD14-negative cells, this indicates that the antibody is a CD14-specific antagonist. This type of cell can be constructed using standard procedures or animals.
[0109] In other instances, potential CD14 antagonist antibodies are evaluated in vivo, such as, for example, in animal models. In such in vivo models, the effects of the antibody can be evaluated in circulation (e.g., blood) or other organs, such as the liver, kidney, or heart. In specific instances, ischemia models are used to evaluate antibody activity.
[0110] Exemplary CD14 antagonist antibodies achieve a reduction of CD14 activity or level by at least 5%, at least 10%, at least 25%, at least 50%, at least 60%, at least 75%, or at least 85% or more compared to the absence of the antibody. In some instances, the antibody can cause a reduction in CD14 agonist activity or level such that the CD14 agonist activity or level is no longer detectable in the presence of the antibody. Such a reduction can be observed in the sample being tested, or, for example, in an animal model where the method is performed, particularly in tissues from the animal, such as the circulatory system or other organs, such as the liver, kidney, or heart.
[0111] Preferably, the antibody is a CD14-specific antagonist as described above. However, this does not mean that the CD14-specific antagonist is completely devoid of off-target antagonistic activity. In this respect, the CD14-specific antagonist may have negligible or small direct binding and action on other cellular components, such that its antagonistic effect on the activity, signaling, or expression of non-CD14 cellular components is less than 15%, less than 10%, less than 5%, less than 1%, or less than 0.1% of the direct binding and action of the agent on the activity, signaling, or expression of CD14.
[0112] The level or amount of CD14 can be measured by evaluating the expression of the CD14 gene. Gene expression can be evaluated by observing the production or level of mRNA or protein. Expression products such as mRNA and protein can be identified or quantified by methods known in the art. Such methods can utilize hybridization to specifically identify the mRNA of interest. For example, such methods can include PCR or real-time PCR methods. Methods for identifying or quantifying the protein of interest can include using an antibody that binds to the protein. For example, such methods can include Western blotting. Regulation of CD14 gene expression can be compared in the presence and absence of an antibody. Therefore, antibodies that reduce CD14 gene expression compared to levels observed in the absence of an antibody can be identified. Such antibodies can be suitable CD14 antagonists according to this disclosure.
[0113] A method for identifying suitable antagonist antibodies for use according to this disclosure can evaluate CD14 agonist activity. For example, such a method can be performed using peripheral blood mononuclear cells. Such cells produce cytokines such as IL-1α, IL-6, TNF-α, IFN-β, IL-1β, IL-17, and IL-8 in response to stimulation, for example, LPS. Therefore, the method can include combining peripheral blood mononuclear cells with an antibody or a mediator and adding LPS. The cells can then be incubated for a specified time (e.g., 24 hours) to allow the production of pro-inflammatory mediators, such as cytokines. The levels of cytokines such as IL-1α, IL-6, TNF-α, IFN-β, IL-1β, IL-17, and IL-8 produced by the cells during this time period can then be evaluated. If the antibody has anti-CD14 properties, the production of such cytokines should be reduced compared to cells treated with the mediator.
[0114] 2.2 adjuvants and interventions
[0115] CD14 antagonist antibodies can be administered alone or in combination with other active agents (also known as "adjuvants") or other interventions. In one instance, the antagonist antibody was administered in combination with thrombolytic agents such as tissue plasminogen activator (tPA, such as alteplase, desmoplase, tenecteplase, or reteplase), streptokinase, urokinase, plasmin, and microplasmin. Other adjuvants include neuroprotective agents such as, but not limited to, NMDA antagonists (e.g., NA-1), anti-CD49d antibodies (e.g., nastatin), NXY-059, and edavarone; neurorepair agents such as stem cells, pifithrin-α, bone morphogenetic protein 7 (BMP7), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and cocaine- and amphetamine-regulated transcripts (CART); antiplatelet agents such as aspirin; and anticoagulants such as heparin, dabigatran, apixaban, edoxaban, and rivaroxaban. In another example, antibody administration is combined with interventions such as thrombectomy, hypothermia therapy, remote ischemic preconditioning, and / or extracranial or intracranial ultrasound thrombolysis.
[0116] When combination therapy is desired, CD14 antagonist antibodies are administered alone, simultaneously, or sequentially with one or more adjuvants or interventions. In some embodiments, this can be achieved by systemic administration of a single composition or pharmacological formulation comprising two types of agents, or by simultaneous administration of two separate compositions or formulations, one comprising a CD14 antagonist antibody and the other comprising an adjuvant. In other embodiments, treatment with CD14 antagonist antibodies can be administered before or after treatment with adjuvants, at intervals ranging from minutes to hours or even days or weeks. For example, nerve repair agents can be administered hours, days, or weeks after administration of CD14 antagonist antibodies. Conversely, thrombolytic agents can be administered before or simultaneously with CD14 antagonist antibodies.
[0117] In some cases, the antibody and adjuvant are administered approximately 1–12 hours apart or approximately 2–6 hours apart. However, in other cases, a significantly prolonged treatment period may be desired, with intervals between individual administrations of one day or more (e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or 8 days) or one week or more (e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or 8 days). In embodiments where the adjuvant is administered alone alongside the CD14 antagonist antibody, it should be understood that the adjuvant may be administered via a different method than that used for the CD14 antagonist antibody.
[0118] In cases where two or more therapeutic agents are administered to a subject in combination or in parallel, they may be administered simultaneously as a single composition, simultaneously as separate compositions, or separately as separate compositions in time.
[0119] 2.3 Composition
[0120] As described herein, CD14 antagonist antibodies, whether used alone or in combination with an adjuvant, can treat acute neuroinflammatory injuries, such as, but not limited to, stroke (e.g., ischemic or hemorrhagic stroke), hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage, and cerebral hemorrhage. CD14 antagonist antibodies, along with optionally an adjuvant, can be administered alone or in combination with a pharmaceutically acceptable carrier. Therefore, CD14 antagonist antibody compositions for the treatment of acute neuroinflammatory injuries are also provided herein.
[0121] CD14 antagonist antibodies can be formulated in a conventional manner using one or more pharmaceutically acceptable carriers, stabilizers, or excipients (mediators) to form pharmaceutical compositions known in the art (particularly with respect to protein active agents). One or more carriers are "acceptable" in the sense that they are compatible with the other components of the composition and harmless to their recipient (e.g., a patient). Suitable carriers typically include saline or ethanol polyols such as glycerol or propylene glycol.
[0122] Antibodies can be formulated in neutral or salt form. Pharmaceutically acceptable salts include acid addition salts (forming with a free amino group) and those formed with inorganic acids such as hydrochloric acid or phosphoric acid, or with organic acids such as acetic acid, oxalic acid, tartaric acid, or maleic acid. Salts formed with a free carboxyl group can also be derived from inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, or iron hydroxide; and organic bases such as isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine, or procaine.
[0123] The composition can be suitably formulated for systemic administration, including intravenous, intramuscular, subcutaneous, or intraperitoneal administration, and conveniently comprises a sterile aqueous solution of antibodies, preferably isotonic with the recipient's blood. Such formulations are typically prepared by dissolving a solid active ingredient in water containing physiologically compatible substances such as sodium chloride, glycine, etc., and having a buffered pH compatible with physiological conditions to produce an aqueous solution, and sterilizing the solution. These can be prepared in single-dose or multi-dose containers, such as sealed ampoules or vials.
[0124] The composition may incorporate stabilizers such as, for example, polyethylene glycol, proteins, sugars (e.g., trehalose), amino acids, inorganic acids, and mixtures thereof. The stabilizers are used in aqueous solutions with appropriate concentrations and pH. The pH of the aqueous solution is adjusted to the range of 5.0-9.0, preferably 6-8. Anti-adsorption agents may be used when formulating the antibody. Other suitable excipients may typically include antioxidants such as ascorbic acid. The composition may be formulated as a controlled-release product, which can be achieved by using polymer complexes or absorbent proteins. Suitable polymers for controlled-release formulations include, for example, polyesters, polyamino acids, polyethylene, pyrrolidone, ethylene vinyl acetate, and methylcellulose. Another possible controlled-release method is to incorporate the antibody into particles of a polymeric material such as polyester, polyamino acids, hydrogels, poly(lactic acid), or ethylene vinyl acetate copolymers. Alternatively, it is possible to incorporate these agents into polymer particles, encapsulate these substances in microcapsules (e.g., hydroxymethyl cellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively) prepared by cohesive technology or interfacial polymerization, or in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or coarse drop emulsions).
[0125] CD14 antagonist antibodies and optionally adjuvants can also be applied directly to the airways in aerosol form. For use as an aerosol, the inhibitors of the invention, in solution or suspension form, can be packaged with a suitable propellant and conventional adjuvants in a pressurized aerosol container, such as hydrocarbon propellants like propane, butane, or isobutane. The substances of the invention can also be administered in non-pressurized form, such as via a nebulizer or atomizer.
[0126] Those skilled in the art will recognize that formulations are routinely designed according to their intended use, i.e., the route of administration.
[0127] 3. Treatment methods
[0128] This disclosure provides treatment methods for subjects suffering from acute neuroinflammatory injury. Therefore, these methods, within their scope, include treating subjects (such as human subjects) for stroke (e.g., ischemic stroke or hemorrhagic stroke), hypoxic-ischemic brain injury, traumatic brain injury, subarachnoid hemorrhage, and cerebral hemorrhage.
[0129] Therefore, this paper considers a method for treating acute neuroinflammatory injury in subjects by administering a CD14 antagonist antibody and optionally an adjuvant. The CD14 antagonist antibody and optionally an adjuvant (collectively referred to herein as "therapeutic agents") will be administered in one or more "effective amounts" to achieve a desired purpose in the subject, such as reducing or preventing one or more symptoms of acute neuroinflammatory injury. The dose of the one or more therapeutic agents administered to the patient should be sufficient to achieve a beneficial response in the subject, such as relief of at least one symptom. In some embodiments of this method, the CD14 antagonist antibody is administered alone, i.e., no other active agent or therapeutic agent is administered to the subject during the treatment of acute neuroinflammatory injury. In other instances, the only other active agent or therapeutic agent administered to the subject is a thrombolytic agent.
[0130] The amount or frequency of administration of one or more therapeutic agents may depend on the subject being treated, including their age, sex, weight, and general health condition. In this regard, the exact amount of one or more therapeutic agents to be administered will depend on the judgment of the practitioner. Those skilled in the art will be able to determine, through routine experiments, the effective, non-toxic amount of the CD14 antagonist antibody and, optionally, the adjuvants described herein, to be administered to the subject. In specific instances, the amount of CD14 antagonist antibody administered to the subject is between 0.1 mg / kg and 50 mg / kg, between 0.5 mg / kg and 40 mg / kg, between 2 mg / kg and 20 mg / kg, or between 5 mg / kg and 10 mg / kg. In specific instances, the amounts of CD14 antagonist antibodies administered to subjects were (or approximately) 0.2 mg / kg, 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, 20 mg / kg, 21 mg / kg, 22 mg / kg, and 23 mg / kg. / kg, 24mg / kg, 25mg / kg, 26mg / kg, 27mg / kg, 28mg / kg, 29mg / kg, 30mg / kg, 31mg / kg, 32mg / kg, 33mg / kg, 34mg / kg, 35mg / kg, 36mg / kg, 37 mg / kg, 38mg / kg, 39mg / kg, 40mg / kg, 41mg / kg, 42mg / kg, 43mg / kg, 44mg / kg, 45mg / kg, 46mg / kg, 47mg / kg, 48mg / kg, 49mg / kg or 50mg / kg.
[0131] CD14 antagonist antibodies can be administered to subjects as a single dose or in multiple doses. In certain embodiments, the CD14 antagonist antibody is administered as a single dose (e.g., a single bolus or a single discrete infusion). In embodiments where the CD14 antagonist antibody is administered in multiple doses, preferably no more than three doses are administered, and these are administered within approximately 6, 12, 18, 24, 36, 48, 60, or 72 hours of each other. In certain embodiments, only one, two, or three doses of the CD14 antagonist antibody are administered.
[0132] Typically, CD14 antagonist antibodies are administered to subjects during the acute phase of injury (e.g., 6–48 hours after injury) or the early subacute phase of injury (e.g., 48–96 hours after injury). Therefore, in an exemplary embodiment, CD14 antagonist antibodies are administered to subjects at any time up to 4 days after injury (e.g., 4 days after a stroke). In one example, CD14 antagonist antibodies are administered to subjects up to 6, 8, 10, 12, 18, 24, 36, 48, 60, 72, 84, or 96 hours after injury (e.g., after a stroke). For example, CD14 antagonist antibodies may be administered to subjects in a single dose up to 6, 8, 10, 12, 18, 24, 36, 48, 60, 72, 84, or 96 hours after injury. In another instance, CD14 antagonist antibodies were administered to subjects in two doses at up to 6, 8, 10, 12, 18, 24, 36, 48, 60, 72, 84, or 96 hours after injury. For example, the first dose could be administered up to 24 hours after injury, and the second dose could be administered at an additional 24–48 hours.
[0133] In specific instances, CD14 antagonist antibodies were administered to subjects between 2 and 96 hours, 4 and 96 hours, 6 and 96 hours, 2 and 72 hours, 4 and 72 hours, 6 and 72 hours, 2 and 48 hours, 4 and 48 hours, 6 and 48 hours, 2 and 24 hours, 4 and 24 hours, 6 and 24 hours, 2 and 18 hours, 4 and 18 hours, 6 and 18 hours, 2 and 12 hours, 4 and 12 hours, or 6 and 12 hours post-injury.
[0134] In order to make the present invention readily understood and put into practice, specific preferred embodiments will now be described by way of the following non-limiting examples. Example
[0135] Example 1
[0136] Materials and methods
[0137] CD14 antagonist antibody
[0138] The active agent used in this study was the F(Ab')2 fragment of commercially available mouse anti-mouse CD14 mAb (biG53). The biG53 F(Ab')2 antibody was selected as the best alternative currently available for use in human and in vitro studies against human CD14 mAb (IC14). IC14 blocks the production of PAMP and DAMP-dependent cytokines in healthy human subjects and in vitro human microglia / monocytes. Figure 1 The species specificity of IC14, limited to human, non-human primate, and porcine CD14, restricts its application in rodents. Therefore, an alternative antibody, biG53, was prepared as an anti-mouse CD14 F(Ab')2 fragment. This reagent has a low endotoxin / azide-free formulation, is not immunogenic in mice, and lacks the Fc domain that mediates antibody and complement-dependent cytotoxicity reflecting the properties of Implicit Biosciences IC14. This anti-CD14 F(Ab')2 has been shown to functionally inhibit PAMP-dependent cytokine production in a dose-dependent manner similar to that observed with IC14 in human microglia / monocytes. Figure 1 C).
[0139] Inducing stroke in mice via filament blockage
[0140] The intracavitary middle cerebral artery occlusion (MCAO) animal model is considered one of the best models for studying the most common form of stroke in humans—stroke caused by occlusion of the middle cerebral artery. In this model, under anesthesia, a fine-gauge suture is passed through the external carotid artery of a mouse until it reaches the middle cerebral artery, blocking blood flow to one side of the brain (evaluated using laser Doppler). Multiple groups of mice have the suture removed after 30 minutes, allowing blood flow to be restored. This results in ipsilateral striatal lesions in the mice, and behavioral changes upon awakening, including turning to the left.
[0141] Treatment plan
[0142] Mice were administered either a) a single intravenous dose of biG53 F(Ab')2 antibody via tail vein injection on day 1, 6 hours after stroke, or b) a single intravenous dose of biG53 F(Ab')2 antibody via tail vein injection on day 1, 6 hours after stroke, followed by daily intraperitoneal administration of biG53 F(Ab')2 antibody for 7 days. A control group receiving only the carrier was also included in the study.
[0143] Functional Evaluation
[0144] All behavioral tests were conducted in a treatment-blind manner. Testing was performed before the stroke and at 24 hours, 48 hours, 72 hours, and 7 days after the stroke. The following behavioral tests were used in this interim analysis.
[0145] Mice were scored using two 28-point scales, following the method described by Clark et al. (Neurol. Res. 1997, 19:641-8). The comprehensive score assessed the animals' general health, including any changes in coat, ears, eyes, or posture, level of spontaneous activity, and any epileptic-like behaviors; while the localized score assessed stroke-specific deficiencies, including body symmetry, gait, climbing ability, circling behavior, forelimb symmetry, and whisker response (McCann et al., PLoS One 9, 2014, e110602). Forelimb weight-bearing was evaluated using a rotating bar test, and forelimb dexterity was determined using a suspension line test (Balkaya et al., Behav. Brain Res. 2018, 352:161–171).
[0146] brain processing
[0147] At the end of the study period (7 days post-stroke), mice were humanely euthanized by cervical dislocation, and the forebrain was collected for histological processing. Serial 16 μm coronal sections were prepared at six predetermined levels (from -3.2 mm to 6.8 mm relative to the anterior fontanelle of the skull) to include the frontal and parietal cortex, as well as the dorsal and ventral striatum.
[0148] Infarct area and activation of monocytes / macrophages and microglia
[0149] Using previously defined methods (McCann et al. PLoS One 9, 2014, e110602; Abeysinghe et al. Stem Cell Res. Ther. 2018, 6:186), infarct size and innate immune cell activation were evaluated using double NeuN / IBa-1 immunofluorescence staining of processed sections. Triple copies of sections from each level were visualized using an Olympus (Albertslund, Denmark) microscope, and stroke lesion areas were identified as areas clearly without NeuN staining, which was analyzed using ImageJ software (NIH, Bethesda, MD, USA).
[0150] Example 2
[0151] Effects of CD14 antagonist antibody treatment on mice with MCAO
[0152] Evaluate mice with MCAO, subsequently treated with CD14 antagonist antibodies or mediators alone, to determine functional decline and neurological deficits, as well as infarct size.
[0153] Functional decline and neurological deficits
[0154] like Figure 2 The study showed significant functional decline in control mice treated with the induced neurotransmitter within 7 days of stroke, with peak declines detected at 24 hours using the dangle test and at 48 hours using neurological scoring and rotarodography. Notably, in the group of mice given a single dose of anti-CD14 F(Ab') at 6 hours post-stroke, functional decline was attenuated at 24 hours, with performance in all tests returning to pre-stroke baseline scores and scores in the sham-operated control animals at 72 hours. Interestingly, however, no attenuation of this functional decline was observed in the group of mice given daily doses of anti-CD14 F(Ab')2 over 7 days.
[0155] Infarct area
[0156] NeuN immunofluorescence staining of whole brain sections from anterior to posterior showed a reduction in infarct area in treated animals compared to untreated animals. Figure 3 Quantification of the total lesion area across all sections (for both the vector-treated and anti-CD14-treated animals, n=3 mice) confirmed the histological observations, with the treated animals showing a 3-4 fold reduction in total lesion. Figure 4 Furthermore, the reduction in damage in treated mice was primarily observed in the brain regions that showed the greatest damage in untreated mice. Figure 5 ).
[0157] discuss
[0158] Data indicate that targeting CD14 during the acute phase of stroke improves both functional and histological outcomes. Conversely, prolonged treatment within 7 days is less effective. Functional and neurological deficits are human-relevant measures of successful stroke treatment outcomes. Reductions in both parameters in mice given a single dose 6 hours after stroke suggest the potential of anti-CD14 therapy as an interventional treatment for stroke in both acute and subacute phases. Functional and neurological deficits are more relevant measures than reductions in infarct size, as small infarcts can sometimes lead to significant functional and neurological deficits in stroke patients. However, the reduction in infarct size in treated mice is also encouraging, as evidence of neuronal survival along the corticomotor tract after stroke is now known as a positive predictor of functional recovery (Stinear, Lancet Neurol. 2017, 16:826–836).
[0159] The reduction in infarct area and total brain injury area in treated mice indicates that anti-CD14 therapy reduces the expansion of the ischemic core into the penumbra (risk area) during the acute phase of stroke in mice and has potential therapeutic benefits. Given the mode of action of anti-CD14 therapy in attenuating DAMP signaling, these data suggest that short-term, acute doses of anti-CD14 antibodies can attenuate the pro-inflammatory innate immune response that leads to detrimental outcomes in the first few days after stroke, and this results in clinically relevant beneficial outcomes.
[0160] Most stroke patients are not diagnosed until 6–12 hours after the event. Therefore, any stroke intervention needs to be effective at least 6 hours after the stroke. Current thrombolytic therapy can only be used within 3 hours after a stroke, as use beyond this time may lead to dangerous intracranial hemorrhage. Therefore, the anti-CD14 intervention at 6 hours after stroke demonstrated in this study represents a clinical improvement over current thrombolytic agents that target only the removal of the clot and do not alter the inherent immune system's harmful local and global effects in response to stroke.
[0161] Each patent, patent application, and publication cited in this article is incorporated herein in its entirety by reference.
[0162] Any reference cited herein shall not be construed as an admission that such reference is available as "prior art" in this application.
[0163] Throughout this specification, the purpose is to describe preferred embodiments of the invention without limiting the invention to any single embodiment or particular set of features. Therefore, those skilled in the art will understand that various modifications and alterations can be made to the illustrated specific embodiments without departing from the scope of the invention. All such modifications and alterations are intended to be included within the scope of the appended claims. sequence list <110> Impulse Biosciences Ltd. Brian W. Ziglar David T. Crowe Gary Llewellyn Redlich <120> Methods and agents for treating acute neuroinflammatory injuries <130> 22975-20081.40 <140> Not yet assigned <141> Currently herewith <150> 2019902642 <151> 2019-07-25 <160> 26 <170> PatentIn version 3.5 <210> 1 <211> 106 <212> PRT <213> House mouse (Mus musculus) <400> 1 Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile 1 5 10 15 Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Phe Gly Asn Ser Phe Met 20 25 30 His Trp Tyr Gln Gln Lys Ala Gly Gln Pro Pro Lys Ser Ser Ile Tyr 35 40 45 Arg Ala Ala Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp 65 70 75 80 Asp Val Ala Thr Tyr Phe Cys Gln Gln Ser Tyr Glu Asp Pro Trp Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Gly Asn Gln 100 105 <210> 2 <211> 105 <212> PRT <213> Mus musculus <400> 2 Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Val Ala Ser Gly 1 5 10 15 Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu 20 25 30 Lys Arg Leu Glu Trp Val Ala Ser Ile Ser Ser Gly Gly Thr Thr Tyr 35 40 45 Tyr Pro Asp Asn Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala 50 55 60 Arg Asn Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr 65 70 75 80 Ala Met Tyr Tyr Cys Ala Arg Gly Tyr Tyr Asp Tyr His Tyr Trp Gly 85 90 95 Gln Gly Thr Thr Leu Thr Val Ser Ser 100 105 <210> 3 <211> 106 <212> PRT <213> Mus musculus <400> 3 Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile 1 5 10 15 Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Val Asn Ser Phe Leu 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr 35 40 45 Arg Ala Ser Asn Leu Gln Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp 65 70 75 80 Asp Val Ala Thr Tyr Cys Cys Gln Gln Ser Asn Glu Asp Pro Thr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 4 <211> 112 <212> PRT <213> Mus musculus <400> 4 Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Ser Leu Ser 1 5 10 15 Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp Ser Ala Trp 20 25 30 Asn Trp Ile Arg Gln Phe Pro Gly Asn Arg Leu Glu Trp Met Gly Tyr 35 40 45 Ile Ser Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Ser Arg 50 55 60 Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe Leu Gln Leu 65 70 75 80 Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Val Arg Gly 85 90 95 Leu Arg Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 100 105 110 <210> 5 <211> 101 <212> PRT Mus musculus <400> 5 Gln Thr Pro Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile 1 5 10 15 Ser Cys Arg Ala Ser Gln Asp Ile Lys Asn Tyr Leu Asn Trp Tyr Gln 20 25 30 Gln Pro Gly Gly Thr Val Lys Val Leu Ile Tyr Tyr Thr Ser Arg Leu 35 40 45 His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 50 55 60 Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Phe Ala Thr Tyr 65 70 75 80 Phe Cys Gln Arg Gly Asp Thr Leu Pro Trp Thr Phe Gly Gly Gly Thr 85 90 95 Lys Leu Glu Ile Lys 100 <210> 6 <211> 116 <212> PRT <213> Mus musculus <400> 6 Leu Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Ile 1 5 10 15 Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Asp Ile Ser Trp 20 25 30 Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp 35 40 45 Thr Ser Gly Gly Thr Asn Tyr Asn Ser Ala Phe Met Ser Arg Leu Ser 50 55 60 Ile Thr Lys Asp Asn Ser Glu Ser Gln Val Phe Leu Lys Met Asn Gly 65 70 75 80 Leu Gln Thr Asp Asp Thr Gly Ile Tyr Tyr Cys Val Arg Gly Asp Gly 85 90 95 Asn Phe Tyr Leu Tyr Asn Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu 100 105 110 Thr Val Ser Ser 115 <210> 7 <211> 15 <212> PRT <213> Mus musculus <400> 7 Arg Ala Ser Glu Ser Val Asp Ser Phe Gly Asn Ser Phe Met His 1 5 10 15 <210> 8 <211> 7 <212> PRT <213> Mus musculus <400> 8 Arg Ala Ala Asn Leu Glu Ser 1 5 <210> 9 <211> 9 <212> PRT <213> Mus musculus <400> 9 Gln Gln Ser Tyr Glu Asp Pro Trp Thr 1 5 <210> 10 <211> 5 <212> PRT <213> Mus musculus <400> 10 Ser Tyr Ala Met Ser 1 5 <210> 11 <211> 16 <212> PRT <213> House mouse (Mus musculus) <400> 11 Ser Ile Ser Ser Gly Gly Thr Thr Tyr Tyr Pro Asp Asn Val Lys Gly 1 5 10 15 <210> 12 <211> 7 <212> PRT <213> House mouse (Mus musculus) <400> 12 Gly Tyr Tyr Asp Tyr His Tyr 1 5 <210> 13 <211> 15 <212> PRT <213> House mouse (Mus musculus) <400> 13 Arg Ala Ser Glu Ser Val Asp Ser Tyr Val Asn Ser Phe Leu His 1 5 10 15 <210> 14 <211> 7 <212> PRT <213> House mouse (Mus musculus) <400> 14 Arg Ala Ser Asn Leu Gln Ser 1 5 <210> 15 <211> 9 <212> PRT <213> House mouse (Mus musculus) <400> 15 Gln Gln Ser Asn Glu Asp Pro Thr Thr 1 5 <210> 16 <211> 6 <212> PRT <213> House mouse (Mus musculus) <400> 16 Ser Asp Ser Ala Trp Asn 1 5 <210> 17 <211> 16 <212> PRT <213> House mouse (Mus musculus) <400> 17 Tyr Ile Ser Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 18 <211> 6 <212> PRT <213> House mouse (Mus musculus) <400> 18 Gly Leu Arg Phe Ala Tyr 1 5 <210> 19 <211> 11 <212> PRT <213> House mouse (Mus musculus) <400> 19 Arg Ala Ser Gln Asp Ile Lys Asn Tyr Leu Asn 1 5 10 <210> 20 <211> 7 <212> PRT <213> House mouse (Mus musculus) <400> 20 Tyr Thr Ser Arg Leu His Ser 1 5 <210> twenty one <211> 9 <212> PRT <213> House mouse (Mus musculus) <400> twenty one Gln Arg Gly Asp Thr Leu Pro Trp Thr 1 5 <210> twenty two <211> 5 <212> PRT <213> House mouse (Mus musculus) <400> twenty two Asn Tyr Asp Ile Ser 1 5 <210> twenty three <211> 16 <212> PRT <213> House mouse (Mus musculus) <400> twenty three Val Ile Trp Thr Ser Gly Gly Thr Asn Tyr Asn Ser Ala Phe Met Ser 1 5 10 15 <210> twenty four <211> 12 <212> PRT <213> House mouse (Mus musculus) <400> twenty four Gly Asp Gly Asn Phe Tyr Leu Tyr Asn Phe Asp Tyr 1 5 10 <210> 25 <211> 238 <212> PRT <213> Artificial Sequence <220> <223> IC14 Light Chain Variable Domain <400> 25 Met Glu Thr Asp Thr Ile Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala 20 25 30 Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser 35 40 45 Val Asp Ser Tyr Val Asn Ser Phe Leu His Trp Tyr Gln Gln Lys Pro 50 55 60 Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Gln Ser 65 70 75 80 Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr 85 90 95 Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys 100 105 110 Gln Gln Ser Asn Glu Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu 115 120 125 Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 130 135 140 Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu 145 150 155 160 Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 165 170 175 Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser 180 185 190 Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala 195 200 205 Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 210 215 220 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 225 230 235 <210> 26 <211> 460 <212> PRT <213> Artificial Sequence <220> <223> IC14 heavy chain variable domain <400> 26 Met Lys Val Leu Ser Leu Leu Tyr Leu Leu Thr Ala Ile Pro Gly Ile 1 5 10 15 Leu Ser Asp Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro 20 25 30 Ser Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr 35 40 45 Ser Asp Ser Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Arg Leu 50 55 60 Glu Trp Met Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Ser Tyr Asn Pro 65 70 75 80 Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln 85 90 95 Phe Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr 100 105 110 Tyr Cys Val Arg Gly Leu Arg Phe Ala Tyr Trp Gly Gln Gly Thr Leu 115 120 125 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 130 135 140 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 145 150 155 160 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 165 170 175 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 180 185 190 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 195 200 205 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 210 215 220 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 225 230 235 240 Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 245 250 255 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 260 265 270 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 275 280 285 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 290 295 300 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 305 310 315 320 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 325 330 335 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 340 345 350 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 355 360 365 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 370 375 380 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 385 390 395 400 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 405 410 415 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 420 425 430 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 435 440 445 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 450 455 460
Claims
1. Use of a CD14 antagonist antibody in the preparation of a medicament for treating ischemic stroke in human subjects, wherein the CD14 antagonist antibody is administered to the human subject at most 48 hours after injury, wherein the CD14 antagonist antibody comprises a light chain and a heavy chain, wherein the light chain consists of the amino acid sequence of SEQ ID NO:25; and the heavy chain consists of the amino acid sequence of SEQ ID NO:
26.
2. Use of a CD14 antagonist antibody in the preparation of a medicament for treating ischemic stroke in human subjects, wherein the medicament is formulated for systemic administration to the human subjects, and wherein the medicament does not contain other active agents and the medicament is administered alone to the human subjects, wherein the CD14 antagonist antibody comprises a light chain and a heavy chain, wherein the light chain consists of the amino acid sequence of SEQ ID NO:25; and the heavy chain consists of the amino acid sequence of SEQ ID NO:
26.
3. Use of a CD14 antagonist antibody in the preparation of a medicament for treating ischemic stroke in human subjects, wherein the medicament is administered to the human subjects in a single dose, wherein the CD14 antagonist antibody comprises a light chain and a heavy chain, wherein the light chain consists of the amino acid sequence of SEQ ID NO:25; and the heavy chain consists of the amino acid sequence of SEQ ID NO:
26.
4. The use according to any one of claims 1-3, wherein the CD14 antagonist antibody is humanized or chimeric.
5. The use according to any one of claims 1-4, wherein the CD14 antagonist antibody is an IC14 antibody.
6. The use according to any one of claims 1-5, wherein the drug is administered to the human subject at most 48 hours after the injury.
7. The use according to any one of claims 1-6, wherein the drug is administered to the human subject at most 24 hours after the injury.
8. The use according to any one of claims 1-7, wherein the CD14 antagonist antibody is administered to the human subject between 2 hours and 24 hours after injury.
9. The use according to any one of claims 1, 2 and 4-8, wherein the drug is administered as a single dose.
Citation Information
Patent Citations
Recombinant method for making multimeric proteins
US20060121574A1
Cotton-harvester
US310314A
Methods and compositions for inhibiting CD14 mediated cell activation
US5820858A
Methods and compositions for inhibiting CD14 mediated cell activation
US6444206B1
Hybrid cells producing monoclonal anti-CD14 antibodies
US7326569B2
